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ABSTRACT 
Bernardo A. Mainou: Biological and Molecular Properties of LMP1: CTARs, Strains, and 
Beyond 
(Under the direction of Nancy Raab-Traub) 
 Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that is associated with 
the development of lymphoid and epithelial malignancies including Hodgkin lymphoma 
(HD), post-transplant lymphoproliferative disorder (PTLD), nasopharyngeal carcinoma 
(NPC), and others.  Latent membrane protein 1 (LMP1) is the EBV oncogene as it is 
necessary for EBV-mediated transformation of B-lymphocytes and can itself transform 
rodent fibroblasts.  LMP1 has a short amino-terminal cytoplasmic end, 6 transmembrane 
domains, and a long carboxyl-terminal cytoplasmic tail that contains the two signaling 
domains, the carboxyl-terminal activation regions 1 and 2 (CTAR1 and CTAR2).   
Through CTAR1 and CTAR2, LMP1 activates several signaling pathways including 
NFκB, phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and 
c-Jun N-terminal kinase (JNK) pathways.  In this study, CTAR1 was shown to be necessary 
for Rat-1 fibroblast transformation and activation of the PI3K-Akt pathway, whereas CTAR2 
was dispensable.  LMP1-mediated rodent fibroblast transformation did not require IκBα-
dependent activation of NFκB.  Seven sequence variants of LMP1 have been identified: 
Alaskan, B95.8, China 1, China 2, Med+, Med-, and NC.  The frequency of detection of 
these variants differs in various EBV-associated malignancies from different geographic 
regions.  In this study, all the sequence variants were demonstrated to transform Rat-1 
fibroblasts, induce increased motility of human foreskin keratinocytes, induce homotypic
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adhesion of BJAB cells and activate the PI3K-Akt signaling pathway.  The Alaskan, China 1 
and Med+ variants had limited binding to the E3 ubiquitin ligase component HOS and 
enhanced NFκB signaling.  These findings indicate that the signature amino acid changes of 
the LMP1 variants do not hinder or significantly enhance their in vitro transforming potential 
or signaling properties. 
Finally, dominant negative forms of TRAF2 and TRAF3 inhibited LMP1-mediated 
transformation of rodent fibroblasts.  Activation of PI3K-Akt signaling and deregulation of 
cell-cycle markers were mapped to the TRAF-binding site and residues between CTAR1 and 
CTAR2.  Activation of the MEK1/2-ERK1/2 signaling pathway through the TRAF-binding 
site was required for LMP1-induced transformation of rodent fibroblasts.  These findings 
identify a signaling pathway that is uniquely activated by CTAR1. 
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CHAPTER ONE 
 
 
 
 
 
 
Introduction
Epstein-Barr Virus 
Starting in the 1940s Denis Burkitt identified a novel extranodal lymphoma occurring 
in children in equatorial regions of Africa where malaria was also endemic (25-28, 240).  
Due to the atypical epidemiologic and clinical aspects of the lymphomas Burkitt 
hypothesized the involvement of an infectious agent (26, 28, 29).  Epstein-Barr virus was 
identified in 1964 by Epstein, Achong, and Barr from electron micrographs of Burkitt’s 
lymphoma cells grown in culture that revealed a herpesvirus-like particle that did not react to 
antibodies of other known herpesviruses and did not replicate in cells in culture (69). 
EBV is the prototype member of the gamma herpesvirus subfamily of herpesviruses.  
All members of this subfamily replicate in lymphoblastoid cells, are usually B or T 
lymphocyte tropic, and have a limited host range to the family or order of the host (148).  
The Lymphocryptovirus (LCV), gamma 1, and Rhadinovirus (RDV), gamma 2, genera are 
found within the gamma herpesvirus subfamily.  EBV, a member of the LCV genera, and 
Kaposi’s sarcoma-associated herpesvirus (KSHV), a member of the RDV genera, are the 
only human members of this subfamily (38).  A distinguishing characteristic of EBV is its 
ability to infect and transform resting B lymphocytes into latently infected lymphoblastoid 
cell lines (LCLs) in vitro (116, 308).  EBV is also capable of infecting epithelial cells in vivo 
as well as pharyngeal epithelial cells, skin keratinocytes, and gastric carcinoma cells in vitro 
(148, 169, 210, 266, 306). 
 
Genome Structure 
EBV is an enveloped virus that contains a linear double-stranded DNA genome of 
184 kilobase pairs (kbp) in length (13, 51, 95, 229, 234).  Interestingly, EBV was the first 
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herpesvirus to be completely sequenced and have all of its genome fragments cloned into 
Escherichia coli (10, 13, 23, 51, 80, 232).  EBV and most LCVs have four characteristic 
features to their genomes: single overall format and gene rearrangement, tandem, reiterated 
direct repeats of the same sequence at both termini (TR), six to twelve tandem reiterations of 
internal direct repeats (IR1), and short and long unique sequence domains (US and UL) that 
contain most of the viral coding capacity (40, 41, 51, 96, 148). 
The fact that RDVs have a broader host range, including several primate species and 
subprimate mammalian species, as well as increased genomic divergence compared to LCVs, 
which are restricted to Old World primates and some New World primates, suggests that 
LCVs evolved after RDVs (3, 74, 148).  
 
EBV Life Cycle 
 EBV is transmitted in saliva that contains cell-free virus as well as infected cells that 
lead to infection of oral epithelial cells (240).  An early study suggested that EBV infection 
of a host began with the fusing of EBV positive B cells to epithelial targets (17).  Although 
this study has not been confirmed or refuted by subsequent studies, infection of epithelial 
cells is more efficient in close contact with virus-producing B cells than cell-free virus (128, 
291).  Infection of the oral epithelium can lead to the production of progeny virions through 
lytic replication in the infected oral epithelial cells (163, 164, 265).  The released virions can 
then infect circulating B lymphocytes in the oral epithelium or in lymphoid organs (11, 196, 
208).  In vitro, naïve and memory cells are equally susceptible to EBV infection (308).  
Interestingly, viral attachment and viral entry differs between B lymphocytes and epithelial 
cells.   
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Attachment to B cells requires high affinity binding between the viral envelope 
glycoprotein gp350/220 and the cellular complement receptor type 2 (CR2), also know as 
CD21, which results in the endocytosis of the virus (79, 84, 198, 206, 278).  Endocytosis of 
the virus in B-lymphocytes leads to fusion with the endosomal membrane at a low pH (192).  
In contrast, the role of CR2 in epithelial cells remains elusive and recent data hint at a 
different mechanism of attachment and entry in epithelial cells.  EBV lacking the two viral 
proteins gH and gL lose the ability to bind to several epithelial cell lines, although the 
cellular binding partner has yet to be identified (197, 212).  More recently the EBV 
glycoprotein BMRF2 was shown to interact with the integrin α5β1 and antibodies to the 
inegrins and to BMRF2 partially blocked binding (291).  Another difference between B cell 
entry and epithelial cell entry is that endocytosis is not required for epithelial cell entry and 
fusion takes place at a neutral pH (240).  Interestingly, EBV produced in human leukocyte 
antigen (HLA) class II negative epithelial cells can infect B cells more readily than virus 
produced in HLA class II positive B cells and virus produced in B cells can infect epithelial 
cells more readily than virus produced in epithelial cells (20, 240).  
 Upon viral entry in B lymphocytes the viral genome circularizes to form a viral 
episome and initiates a limited latency program through transcription from the viral Wp 
promoter, which requires the cellular RNA polymerase II (251).  Latently infected B 
lymphocytes have restricted expression of viral gene products, thus promoting evasion of 
immune surveillance (12, 196, 280, 286).  Periodically the latently infected B cells undergo 
reactivation leading to new viral progeny (8, 11).  The released virus can infect surrounding 
B cells, or if reactivation takes place while circulating through the oropharynx, the virus can 
infect oral epithelial cells and/or be shed through saliva (Figure 1). 
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Figure 1.  EBV Life Cycle.  EBV infects the oral epithelium and perhaps circulating B-cells 
in the oropharynx.  Progeny virus then infects naïve or memory B cells in the surrounding 
lymphoid tissues where the latency program drives the growth and proliferation of the 
infected B cells.  A portion of the proliferating B cells are removed by latent-specific-antigen 
primary T cell response, with the surviving portion establishing a stable reservoir of infected 
cells.  Periodic reactivation and recruitment of the latently infected B cell to the oropharynx 
results in infection of the oral epithelium, further viral replication, and shedding of progeny 
virions into the saliva. 
    
Primary Infection 
 Seroconversion surveys, as measured by immunoglobulin G (IgG) antibodies against 
the viral capsid antigen (VCA), have revealed that most children in developing countries are 
infected with EBV by age 3 and close to 100% by age 10 (148).  These primary infections, 
which are mostly asymptomatic, likely occur from parent-to-child transmission of saliva 
(100).  In contrast, in developed countries 50% of children remain seronegative by age 10 
with most seroconverting during adolescence through intimate oral contact.  The delayed 
primary infection results in about 50% of the infections being symptomatic with a subset 
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leading to infectious mononucleosis (IM), of which EBV is the etiologic agent (115, 148, 
240). 
 Most studies of EBV primary infection have focused on IM patients but because IM 
patients do not show symptoms until 4-6 weeks post infection the earliest of events in 
infection are not well elucidated.  By the onset of symptoms, cell-free infectious virus can be 
isolated from saliva and throat washings but the source of the infectious virus remains 
controversial.  For example, tonsils from IM patients revealed infected B-lymphocytes, but 
not infected tonsillar epithelial cells (8, 91, 299).  Before the onset of symptoms and during 
acute IM, patients show a generalized infection of their circulating B-lymphocytes, with 0.1-
1.0% of circulating B cells being EBV positive during the peak of acute IM (58, 152, 273).  
B lymphocytes isolated from IM patients have EBV latency transcripts suggesting that the B 
lymphocytes that are infected during primary infection are already growth-transformed (148). 
 By the onset of symptoms IM patients have high titers of IgM antibodies to the capsid 
antigen VCA as well as increasing IgG titers to VCA and early antigen (EA), although 
neutralizing antibodies against gp350 are relatively low (148, 267).  Another characteristic of 
acute IM is the presence of atypical CD8+ T lymphocytes as a result of a strong cytotoxic T-
lymphocyte (CTL) response against EBV (35, 271).  The CTL response is directed mainly 
towards EBV lytic antigens, although this response starts to decrease post-IM and is 
supplanted by a T-lymphocyte response directed against the EBV latent antigens (270).  
Interestingly, studies have identified a variety of LMP1 sequence variants (59, 60, 195, 263).  
These sequence variants arise from the onset of primary infection or soon thereafter as 
patients with IM already show a varied population of LMP1 sequence variants (264).  The 
sequence variants appear to also have compartmentalization differences (e.g. oral cavity and 
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peripheral blood or peripheral blood and tumor) suggesting that the sequence variations in 
LMP1 provide an advantage to the proliferating cell population (262, 263). 
 
Viral Immune Evasion 
 Intracellular viral infections are kept in check by the CTL response to infected cells 
through their recognition of viral antigen being presented by major histocompatibility 
complex (MHC) class I.  The memory T cell response is mainly directed against the EBV 
nuclear antigens (EBNA) 3A, 3B, and 3C and a lesser response against the latent membrane 
protein 2 (LMP2).  A very weak response has also been detected against an epitope of the 
BAMHI-A reading frame 0 (BARF0) protein (149).  In contrast, responses to EBNA1, 
EBNA2, EBNA-LP, and latent membrane protein 1 (LMP1) are not common (147, 205).  
Viral gene expression in memory B cells tends to be limited to EBNA1.  A string of glycine-
alanine repeats that inhibit the proteasome-dependent degradation of EBNA1, a necessary 
step for proper MHC class I processing, protects EBNA1 from MHC class I presentation 
(165, 166, 259).  It is through this combination of limited viral gene expression and limited 
presentation of viral antigens through MHC class I that EBV avoids eliciting a strong CTL 
response. 
 Another strategy of immune evasion by EBV is its ability to suppress HLA class II 
expression through the viral glycoprotein gp42, which in vitro binds HLA class II in the 
endoplasmic reticulum and prevents its maturation (20).  Also, in B cells one of the three 
EBV glycoproteins  in the gHgLgp42 complex binds HLA class II upon gp350-CR2 binding 
to facilitate viral entry (168).  Another method of immune evasion by EBV includes the 
ability of the secreted viral protein BARF1 to interfere with interferon α (IFNα) (47).  The 
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EBV early lytic protein BZLF1 blocks the antiviral activities of IFNγ by inhibiting its 
downstream signaling events (203). 
The ability of EBV to evade the host immune system while persisting during the 
larger part of the life span of the host also requires EBV to subtly deregulate B cell behavior 
using normal B cell biology.  Towards this goal, EBV encodes a viral protein, IL10, that 
induces B cell growth and differentiation while also blocking antigen presentation from 
monocytes and dendritic cells (174). 
 
Lytic Replication 
  The study of lytic replication in EBV infected cells requires the induction of latently 
infected cells into the lytic program.  In vitro studies have focused on inducing lytic 
replication through the treatment of latently infected cells with phorbol esters.  Phorbol esters 
induce lytic replication through the activation of the protein kinase c (PKC) pathway.  The 
PKC pathway induces lytic replication through the activation of AP-1 sites that are upstream 
of viral immediate-early (IE) genes and through the activation of the viral IE protein BZLF1 
(9, 82, 83).  Induction of lytic replication can also be achieved through activation of the B 
cell receptor with soluble immunoglobulin (277).  Following induction, cells undergo various 
cytopathic changes prior to virion release including margination of nuclear chromatin, 
inhibition of host macromolecular synthesis, replication of viral DNA, assembly of 
nucleocapsids, nucleation of nucleocapsids, and envelopment of the virus through the inner 
nuclear membrane (55, 92, 99, 141, 148, 219, 237, 252). 
 Similar to other herpesviruses, EBV lytic gene expression follows a temporal and 
sequential order (277).  Lytic gene expression can be subdivided into three stages, immediate 
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early (IE), early, and late.  IE genes are defined by viral mRNAs that can be transcribed 
immediately after infection in the presence of a protein synthesis inhibitor (216).  Early genes 
are those that are expressed prior to DNA replication and late genes require viral DNA 
synthesis for their transcription. 
 The primary IE genes of EBV are BZLF1 and BRLF1 (216).  Because lytic EBV 
infection in vitro can only be studied through the induction of latently infected cells, it must 
be noted that the role of the IE genes could be affected by the latency program.  With this in 
mind, BZLF1 and BRLF1 have been identified as potent transactivators of cellular and viral 
gene expression.  Ectopic expression of BZLF1 can activate lytic infection (132-134).  
BZLF1 is a dimerizing DNA binding protein that can bind AP-1-like sites, some found 
within its own promoter, and can autoregulate its own promoter as well as the BRLF1 
promoter (76, 81-83).  BZLF1 can associate with NFκB family members and p53, resulting 
in the inhibition of its transactivating activity, when bound to NFκB, or the inactivation of 
both proteins, when bound to p53 (107, 124, 140, 311).  BRLF1 also contains transactivating 
activity although its activity has not been as well characterized as the transactivating 
activities of BZLF1 (112, 113). 
 In addition to BZLF1 and BRLF1, EBV also encodes the early transactivators 
BSMLF1 and BMRF1 (43, 44).  BSMLF1 is a promiscuous transactivator that works 
synergistically with BZLF1 or BRLF1 (145).  The EBV glycoproteins are all late genes and 
include gp350/220, gp110, gp85, gp42, gp55/80, gp150, gp15, gp84/113, and gp64.  
gp350/220 mediates binding to the EBV receptor CR2, is the major component of the EBV 
envelope, and most neutralizing antibodies are directed against gp350/220 (181, 281-283). 
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Establishment of Latency 
 The EBV latent program is characterized by the constitutive expression of a subset of 
viral gene products.  These latent viral gene products include six EBV nuclear antigens 
(EBNAs 1, 2, 3, 3A, 3B, 3C and –LP) and three latent membrane proteins (LMPs 1, 2A, and 
2B), as well as a family of highly spliced 3’ co-terminal transcripts, BamHIA transcripts or 
BARTs, and a group of small non-polyadenylated RNAs (EBER1 and EBER2).  Latency is 
subdivided into three different types depending on the pattern of gene expression (Table 1).  
Type I latency is characterized by expression of EBNA1 from the Qp promoter as well as the 
EBERs and the BARTs.  In type II latency, the expression is limited to EBNA1, the EBERs, 
the BARTs, LMP1 and LMP2A.  In type III latency all of the latent proteins, including 
EBNA-2, -LP, and 3A-C, are expressed in addition to the BARTs and EBERs, and infection 
of B lymphocytes in vitro results in a type III program (148, 308).  A subset of latent proteins 
are essential for EBV-mediated transformation of B-lymphocytes, and these are EBNA1, 
EBNA2, EBNA3A, EBNA3C, and LMP1 (47, 235). 
 I II III 
EBNA1 Qp Qp Wp, Cp 
EBNA2, EBNA-LP, EBNA3s No No Yes 
LMP1 No Yes Yes 
LMP2 No Yes Yes 
EBERs Yes Yes Yes 
BARTs Yes Yes Yes 
Malignancy BL HD, NPC LCL 
Table 1.  Types of EBV latent gene expression and their associated malignancies.  The 
three types of latency associated with EBV (I, II, or III) are listed with the viral products 
associated with each latency type.  The viral promoters used by EBNA1 are listed for each 
latency type.  (Adapted from (148)). 
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 EBNA1 
 EBNA1 is expressed in all EBV infected cells where its main role is the maintenance 
and replication of the viral genome through its sequence-specific binding to the origin of 
viral replication, Ori P (236, 308).  By tethering the viral episome to mitotic chromosomes in 
dividing cells, each daughter cell retains the viral genome (213, 304, 305).  EBNA1 can also 
regulate the transcription of other EBNAs, including itself, as well as LMP1 through its 
interaction with viral promoters (308).  As mentioned previously, glycine-alanine repeats 
between the amino- and carboxyl-terminal ends of EBNA1 stabilize the mature protein by 
preventing its proteasomal breakdown (166).  Expression of EBNA1 in murine cells does not 
induce a CTL response, perhaps as a result of its impaired proteasomal breakdown, which is 
required for antigen processing into MHC class I (166, 290).  These characteristics of 
EBNA1 allow latently infected cells, in particular those of latency type I, to avoid host 
immune recognition. 
 
EBNA2 and EBNA-LP 
 Although both EBNA2 and EBNA-LP are expressed during type III latency, EBNA2 
is essential for the transformation of B-lymphocytes by EBV.  Whereas EBNA-LP is not 
essential, it aids in the outgrowth of LCLs (5, 48, 187).  EBNA-LP has two runs of basic 
amino acids that are responsible for its nuclear localization and EBNA-LP coactivates 
EBNA2-mediated transcription from the Cp and LMP1 promoter (111, 211, 224). 
 EBNA2 is a potent viral transactivator of both cellular and viral promoters through its 
interaction with a sequence-specific DNA-binding protein Jκ-recombination-binding protein 
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(RBP-Jκ) as well as PU.1 (104, 125, 135).  Through its interaction with RBP-Jκ and PU.1 
EBNA2 transactivates cellular such as CD21, CD23, and c-myc as well as the EBV genes 
LMP1 and LMP2A and this interaction is necessary for EBV-mediated B-lymphocyte 
transformation (1, 49, 71, 72, 296, 303). 
 
EBNA3A, EBNA3B, and EBNA3C 
 Similar to EBNA2 and EBNA-LP, the three EBNA3s are only expressed in latency 
type III.  EBNA3B is neither necessary for B-lymphocyte transformation nor required for 
LCL outgrowth, lytic replication, or cell survival (288).  In contrast, EBNA3A and EBNA3C 
are essential for EBV-mediated B-lymphocyte transformation (289).  Although the EBNA3 
mRNAs are present at very low levels the protein products have a very long half life (148).   
The EBNA3s negatively modulate the transcriptional activation of EBNA2 and 
EBNA-LP through competition for RBP-Jκ and Notch (136, 154, 190, 239, 241, 292, 312).  
EBNA3A represses the viral Cp promoter in both B-lymphocytes and epithelial cells (46).  
EBNA3C can cooperate with RAS to disrupt cell-cycle checkpoints and induce rodent 
fibroblast transformation (220, 221).  EBNA3C in conjunction with EBNA2 can induce 
transcription of LMP1 through binding the PU.1 site within the LMP1 promoter (190, 313). 
 
LMP1 
 LMP1 is the main oncogene of EBV as it can transform rodent fibroblasts in vitro and 
is essential for EBV-mediated transformation of B-lymphocytes (142, 294).  Expression of 
LMP1 in epithelial cells significantly affects cell growth, inhibits differentiation and can 
induce morphologic transformation (52, 72).  Expression of LMP1 in cells has pleiotropic 
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effects resulting in the induction of a variety of cellular markers including cell-adhesion 
molecules (e.g. ICAM1/CD54, E-cadherin), anti-apoptotic proteins (e.g. Bcl-2 and A20), 
growth factors (e.g. EGFR), and others (64, 65, 86, 114, 194, 295). 
 Although LMP1 is regulated by a weak promoter, LMP1 mRNA is significantly more 
abundant than EBNA mRNAs in latently infected B-lymphocytes (78, 250).  In epithelial 
cells, transcription of LMP1 is mediated by multiple TATA-less sites in the nearest terminal 
repeat (TR), which results in a transcript with a long 5’ untranslated exon (94, 247).  LMP1 is 
an integral membrane protein composed of a short 20 amino-acid amino-terminal end, six 
hydrophobic transmembrane domains, and a 200-amino-acid long carboxyl-terminal tail 
(Figure 2A) (78, 240).  The half-life of LMP1 is less than two hours and post-translational 
modifications include phosphorylation at multiple serine and threonine residues, but not 
tyrosine residues (14, 42, 186, 199, 200).  LMP1 associates with cellular cytoplasmic 
cytoskeleton and is present in cholesterol-rich lipid rafts without requiring ligand stimulation 
(22, 120, 171, 172).  Interestingly, only about half of the cellular LMP1 is found in the 
plasma membrane with the rest being associated with other cellular membranes, suggesting 
that LMP1 may regulate its signaling activity through its cellular localization (119, 172, 185). 
 The carboxyl-terminal domain of LMP1 contains two main signaling domains, the 
membrane proximal carboxyl-terminal activating region 1 (CTAR1 or TES1) and the 
membrane distal carboxyl-terminal activating region 2 (CTAR2 or TES2).  Although LMP1 
has little sequence homology to any known protein, it is functionally similar to the tumor 
necrosis factor receptor (TNFR) and CD40 (204).  Both LMP1 and CD40 signal through 
recruiting adapter proteins called TNFR associated-factors (TRAFs) to a PxQxT motif (57, 
85).  While CTAR1 recruits TRAFs 1, 2, 3, and 5 directly through its PxQxT motif, CTAR2 
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indirectly recruits TRAFs 2 and 6 by binding adapter molecules such as the TNFR associated 
death domain (TRADD), the receptor interacting protein (RIP), and BS69 (130, 131, 293).  
In contrast to TNFR, LMP1 does not require a ligand to associate with the TRAFs, thus 
LMP1 is constitutively active (57, 85, 193, 204). 
 Although both CTAR1 and CTAR2 utilize TRAFs to induce signaling, the two 
domains have distinct signaling properties (Figure 2B).  Despite both CTAR1 and CTAR2 
being able to activate the NFκB family of transcription factors, when measured by NFκB 
reporter assay, CTAR2 contributes about 70% of the NFκB activity while CTAR1 
contributes the remaining 30% (110, 159, 193).  Interestingly, in epithelial cells CTAR1 
activates three different NFκB dimer forms (p50/p50, p50/p52, and p52/p65) whereas 
CTAR2 only activates p52/p65 dimers (193, 217).  CTAR1, but not CTAR2, retains the 
ability to upregulate the epidermal growth factor receptor (EGFR) and this upregulation may 
be due to the CTAR1-specific activation of p50/p50/Bcl-3 complexes, which have been 
shown to be bound to the NFκB sites within the egfr promoter (194, 285).  Furthermore, 
although CTAR2 is not necessary for LMP1-mediated transformation of B-lymphocytes, 
LMP1 deleted for CTAR2 cannot support LCL outgrowth (142, 143).   
In addition to the NFκB signaling pathway LMP1 can activate a myriad of other 
signaling pathways including Cdc42, p38 pathway, c-jun N-terminal kinase (JNK) pathway, 
phosphoinositol 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK)/ 
extracellular signal-regulated kinase (ERK) 1 (MEK1) pathway (53, 66, 67, 173, 238, 249).  
LMP1 also induces an increase in the cell surface expression of a variety of markers 
including CD23, CD39, CD40, CD44, CD54 (ICAM1), MHC class II, and LFA3, and it can 
also induce secretion of the cytokine IL10 and decrease levels of CD10 (148).  LMP1 can 
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inhibit apoptosis in B-lymphocytes as well as protect epithelial cells from p53-mediated 
apoptosis, in part through increasing the levels of A20 and Bcl-2 (86, 87, 103, 114, 159, 191, 
245).   
LMP1 can induce expression of the inhibitor of differentiation (Id) family of proteins 
as well as induce deregulation of a variety of markers associated with cell-cycle progression 
(70, 167, 240).  Expression of LMP1 in epithelial cells blocks epithelial cell differentiation 
(52).  In transgenic mice, expression of LMP1 in skin leads to epidermal hyperplasia and 
when expressed under control of the immunoglobulin (Ig) heavy chain promoter increases 
the incidence of B cell lymphomas (155, 302). 
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Figure 2.  Signal transduction pathways associated with LMP1.  (A) LMP1 is composed 
of a short amino-terminal cytoplasmic region, 6 transmembrane domains (white bar), and a 
long carboxyl-terminal tail that contains its two main signaling domains, CTAR1 (1) and 
CTAR2 (2).  (B) CTAR1 directly binds several TRAFs and activates various signaling 
pathways including PI3K and NFκB signaling pathways.  CTAR2 recruits TRAFs through 
adapter molecules, such as TRADD and RIP, and also activates a variety of signaling 
pathways including NFκB and JNK.  The activation of NFkB leads to several cellular targets 
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being induced including the antiapoptotic A20 and Bcl-2, as well as EGFR, ICAM1, CD23, 
and others. 
  
LMP2 
 LMP2 refers to two integral membrane proteins, LMP2A and LMP2B, expressed 
during type II and type III latency.  LMP2A and LMP2B are not necessary for EBV-
mediated B cell transformation (175).  Also, viral replication is not altered when latently 
infected cells carrying LMP2A mutants are subjected to viral reactivation (151, 177-179).  
Interestingly, expression of LMP2A in B-lymphocytes in transgenic mice abrogates normal 
B-lymphocyte development leading to Ig-negative cell colonization of peripheral lymphoid 
organs, suggesting that LMP2A can mimic signaling through the B-cell receptor (BCR) (33, 
308).  In contrast, LMP2A can transform epithelial cells while enhancing their adhesion and 
motility (256).  Although little is known about LMP2B, recent reports suggest that it plays a 
role in modulating LMP2A activity (244). 
LMP2A, which is expressed in type II and type III latency, is composed of a long 
amino-terminal tail that contains an immunoreceptor-tyrosine activation motif (ITAM), 12 
transmembrane domains and a short 27-amino acid.  In B-lymphocytes LMP2A associates 
with and is a substrate of the Src family of tyrosine kinases and the ITAM motif plays a key 
role in the ability of LMP2A to induce survival signals in the absence of BCR signaling (24, 
88, 89, 176).  In epithelial cells, LMP2A is phosphorylated in response to cell adhesion 
mediated by carboxyl-terminal Src kinase (Csk) (257).  LMP2A expression in telomerase-
immortalized human keratinocytes leads to activation of PI3K and β-catenin signaling 
pathways, including the inactivation of glycogen synthase kinase β (GSK3β) and a member 
of the forkhead transcription factor family (201, 202).  In HaCaT keratinocytes, ectopic 
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expression of LMP2A also activates PI3K and Akt signaling while blocking differentiation 
and inducing tumor formation in nude mice (256). 
 
EBERs 
 EBERs, EBER1 and EBER2, are small non-polyadenylated RNAs that are the most 
abundant RNAs in latently infected cells.  Although they are present in all three forms of 
latency they are not necessary for EBV-mediated transformation of B cells (274).  EBERs 
assemble into ribonucleoprotein complexes with the La autoantigen and ribosomal protein 
L22 in the nucleus of infected cells and also bind the double-stranded RNA binding protein 
kinase (PKR) (98, 276).  Both EBERs share sequence and structural homology with the 
adenovirus protein VA and cellular U6 RNAs, which also associate with La (98).  
Adenovirus VA blocks PKR activity and the ability of the EBERs to bind PKR suggest a role 
for the EBERs in countering cellular antiviral mechanisms and promoting persistence (254).  
Furthermore, expression of the EBERs in BL cell lines promote cell survival, increase 
tumorigenicity and induce interleukin-10 (IL-10) expression (246, 276). 
 
BARTs 
 BamHIA rightward transcripts (BARTs) or complementary strand transcripts (CSTs) 
are a group of abundantly expressed and highly spliced RNAs that were identified in NPC 
but have also been found in Burkitt’s lymphoma, Hodgkin lymphoma, and nasal T-cell 
lymphoma, as well as in the peripheral blood of healthy individuals (39, 54, 122).  Although 
the BARTs are found in a variety of EBV-associated malignancies and are expressed in all 
types of latency, their expression is not necessary for EBV-mediated transformation of B-
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lymphocytes in vitro (242).  Distinct splice variants can be identified by PCR and RNase 
protection assay (247, 268).  Three transcripts have been of particular interest as they appear 
to encode open reading frames, rkbarf0, rb2 (A73), and rk103 (RPMS1), with RK-BARF0 
and RB2 mRNAs being the most abundant in NPC (248). 
 Yeast-two-hybrid of RK-BARF0, RB2, and RK103 revealed various cellular binding 
partners and RK-BARF0 has been demonstrated to bind to Notch 1 and Notch4 as well as 
induce the nuclear translocation of unprocessed Notch (158).  Interestingly, RK-BARF0 also 
induces the proteasomal degradation of Notch which correlates with EBV-positive cell lines 
having reduced levels of Notch (284).  RK103 binds RBPJκ, a Notch downstream target, and 
inhibits the transactivating activities of both EBNA2 and NotchIC (310).  RB2 can bind the 
receptor for activated protein kinase C (RACK) (268).  Another product of a BART, BARF1, 
has been shown to be a secreted protein and has oncogenic activity when expressed in rodent 
fibroblasts (56, 260). 
 Recent studies have focused on the finding that EBV encodes at least 17 micro RNAs 
(miRNAs) with 14 of these being found as BARTs (32, 105, 225).  The BART miRNAs are 
expressed at high levels in latently infected epithelial cells but lower levels in latently 
infected B-lymphocytes, with miRNAs only expressed in latency III (32, 153).  These 
findings point towards a mechanism through which EBV can regulate gene expression in a 
host cell without requiring viral gene expression. 
 
Genetics with EBV 
 The limited host range of EBV to B-lymphocytes and the nonpermissiveness of these 
cells for lytic replication have hindered the construction of EBV recombinants.  Specifically 
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mutated recombinant EBV can be produced by transfecting latently infected lymphocytes 
with mutated DNA fragments that are cloned and amplified in Escherichia coli followed by 
lytic program induction where homologous recombination gives rise to recombinant EBV 
(161, 188, 189, 288, 297).  Alternatively, latently infected lymphocytes with the replication-
competent but transformation-deficient EBV P3HR1 can be used as the source of the parental 
strain (242, 289).  Recently the EBV genome was cloned into a bacterial artificial 
chromosome (BAC) vector and was shown to yield recombinant EBV (138).  The EBV-BAC 
will likely facilitate the study of specific mutants in the context of EBV infection, 
establishment of latency, and reactivation. 
 
EBV-Associated Malignancies 
Infectious Mononucleosis (IM) 
 As mentioned previously, primary infection with EBV is usually asymptomatic.  
Delay of primary infection until adolescence sometimes results in IM.  During IM, patients 
shed high titers of virus from lytic infection at the oropharynx while also maintaining high 
numbers of latently infected, EBNA2 and LMP1 positive, lymphoblasts in the tonsillar 
lymph nodes (8, 157).  The symptoms associated with IM are the result of an increase in pro-
inflammatory cytokines, such as IL-1, IFN-γ, TNFα, released by T-lymphocytes in response 
to lytic and latent viral antigens (2, 208).  The CD8+ T-cell memory response is then 
maintained during the life span of the host and it usually constitutes up to 5% of the total 
circulating CD8+ T-cell population (121). 
 
Chronic Active EBV 
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 Classic IM infections generally result in the infection resolving and the host returning 
to an asymptomatic state.  A few exceptional patients present with chronic fatigue symptoms, 
and although there is no clear link to EBV, some children suffer from recurrent fever, 
lymphadenopathy, and hepatosplenomegaly as well as high titers of IgG against VCA and 
EA for several years after primary infection (4, 117, 214, 258).  These patients also have high 
EBV genome loads in their peripheral blood mononuclear cells (PBMC) (183, 258).  
 
X-linked Lymphoproliferative Syndrome (XLP) 
 XLP is a lymphoproliferative disease that afflicts young boys and is characterized by 
extreme sensitivity to EBV (15, 230).  50-60% of patients present with hyperacute-IM 
followed by liver failure as a result of widespread lymphocytic infiltration and hepatic 
necrosis (237).   
 
Virus Associated Hemophagocytic Syndrome (VAHS) 
 VAHS is a T-cell lymphoma that is mainly found in Southeast Asian populations.  
VAHS arises either after acute primary infection or during chronic active EBV infection with 
VAHS-like symptoms (137, 139).  These CD4+ and CD8+ T-cell lymphomas are of 
monoclonal origin, have a latency I/II pattern of gene expression and arise from a pre-
malignant pool of EBV-infected T-lymphocytes (150, 308).  Symptoms include fever, 
lymphadenopathy, hepatosplenomegaly, hemophagocytosis in tissues, and pancytopenia 
often leading to death (237). 
 
Hodgkin Lymphoma (HD)
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 In Hodgkin Lymphoma malignant mononuclear Hodgkin and multinuclear Reed-
Sternberg cells (HRS) are surrounded by very dense non-malignant lymphocytic infiltrate.  
HD is further classified by the appearance of the infiltrate into nodular sclerosing (NS), 
mixed cellularity (MC), lymphocyte depleted (LD) and lymphocyte predominant.  About 
40% of cases of HD in developed countries are EBV-positive with the number of EBV-
positive cases being larger in developing nations (126).  Most of the EBV-positive cases in 
developed nations are MC and LD, but only a minority of the NS cases that make up the peak 
of HD incidence in developed countries are EBV positive (126).  In developing countries 
childhood HD is more prevalent and there is a steady increase of MC incidence with age 
(237). 
 Individuals with a prior history of IM are at a higher risk of developing HD within 
three years of primary infection (97).  HRS cells, which are of B-cell origin, stain positive for 
EBV DNA, have a type II pattern of gene expression and show no chromosomal 
abnormalities (7, 21, 156, 300, 301).  Increased levels of Bcl-2, p53, IL-10 and increased 
NFκB activity are associated with HRS cells (228).  NFκB signaling plays a key role in the 
growth of HD cell lines, and EBV-negative HRS cell lines frequently have mutant IκBα 
alleles or amplification of the REL gene (16, 30, 68, 128, 156). 
  
Nasopharyngeal Carcinoma (NPC)
 NPC is a subset of gastric adenocarcinomas and certain salivary-gland carcinomas as 
a result of EBV infection of the epithelium (231).  NPC is rare in North America and Europe 
where its frequency is less than 0.5 incidents per 100,000 cases.  In contrast, parts of China 
and Southeast Asia the incidence is 25 per 100,000 cases per year, with Chinese Cantonese 
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males having an increased incidence (309).  In addition to genetic factors, environmental 
factors such as a diet high in salted fish and repeated exposure of the nasopharynx to 
chemical carcinogens have been suggested to play an important role in the etiology of NPC 
(237, 309).   
The World Health Organization subdivides NPC into three types with EBV having 
the most consistent association with type III NPC, which is EBV positive almost 100% of the 
time.  Type III NPC is non-keratinizing, is often undifferentiated, and contains a large 
lymphocytic infiltrate that plays an important role in the propagation of the tumor (207, 222, 
231, 308).  NPC patients have increased EBV antibody titers with tumors indicating 
monoclonal expansion (215, 233).  Although NPC has a type II latency pattern of gene 
expression only 20-40% of NPC tumors express LMP1 (231).  Although antibodies against 
viral lytic antigens can be identified, only episomal DNA can be detected from tumors and 
tumors are generally negative for viral lytic antigens.  These findings suggest that some 
fraction of the NPC tumor may be going through lytic reactivation (45, 106, 118, 233).  NPC 
tumor cells express HLA class I and class II antigens process antigens efficiently and also 
express markers associated with epithelial-lymphocyte interactions such as CD40, 
CD54/ICAM1, CD70, CD86, CD95/FasR  (2, 147, 162, 253). 
HLA haplotype seems to play a role in NPC pathogenesis as genes closely linked to 
HLA can be associated with an increased risk for development of NPC (60, 180).  Haplotyes 
HLA-A2, BW46, A19, B17 class I and HLA-DR β10803 class II are associated with an 
increased risk for NPC, while HLA A11 and B13 class I have decreased risk (60, 237).  
Although many of the high-risk haplotypes are prevalent in Southeast Asia and certain areas 
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of China, Chinese immigrants and second generation Chinese immigrants have a reduced risk 
for NPC suggesting an important role of environmental factors in NPC oncogenesis (237). 
The role of EBV in initiating NPC tumor development is not well understood.  
Although EBV cannot transform epithelial cells, EBV can be detected in pre-malignant 
lesions of the nasopharynx suggesting that EBV may play a role in the early stages of NPC 
oncogenesis (223, 302).  Genetic mutations, such as those leading to an increase in p53 levels 
or loss of the cyclin-dependent kinase inhibitor (cdki) p16INK4a, may be necessary for NPC 
pathogenesis (61, 106, 272).  p53 mutations are frequently detected in NPC tumors passaged 
in nude mice but are infrequently detected in primary NPC tumors or metastatic tumors, 
suggesting that p53 mutations are not necessary for NPC oncogenesis (61).   
 
Gastric Carcinoma
 EBV is found in approximately 10% of typical gastric carcinomas, with a pattern of 
gene expression similar to NPC (127, 261, 287).  EBV-positive gastric carcinomas have 
different characteristics than their EBV-negative counterparts, including loss of expression of 
p16INK4a and improved patient survival (160, 255).  The absence of EBV infection in pre-
malignant gastric lesions suggests that EBV plays a role in the later stages of oncogenesis 
(314). 
 
Post-Transplant Lymphoproliferative Disorders (PTLD)
 Sustained immunosuppression of transplant patients can lead to an increased 
incidence of lymphomas or PTLDs.  The major risk factor associated with PTLD is the 
intensity of T-lymphocyte suppression due to the different kinds of transplantation.  For 
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example, PTLD has a 1-2% incidence rate in renal and liver transplants, 3-8% incidence in 
heart and lung transplants due to the need for greater immunosuppression (237).  PTLD 
occurs in only 1% of bone marrow transplants although the incidence increases to 12-24% if 
the bone marrow is depleted of T-lymphocytes.  Because bone marrow transplants usually 
require total ablation of host lymphoid cells, PTLD are likely to be derived from the EBV-
infected donor B cells in the transplanted bone marrow (101, 108).  Patients who are EBV 
seronegative before transplantation are also at a higher risk of PTLD (123).  Reduction of 
immunosuppressive therapy can result in lesion regression, and depletion of the graft of B- 
and T-lymphocytes can reduce PTLD incidence (108, 269). 
 PTLD usually appears one to two years post transplantation and lesions are 
subdivided into three categories: early lesions involving plasmacytic hyperplasia and reactive 
elements similar to that observed in IM tissues, polymorphic lesions of either B-cell 
hyperplasia or B-cell lymphoma, or monomorphic lesions that are immunoblastic lymphomas 
(237).  90% of monomorphic lesions are associated with EBV with the lesions showing a 
type III latency with EBNA1, EBNA2, and LMP1 found in most EBV-positive lesions (170, 
279, 307).  p53 and c-myc mutations are sometimes associated with PTLD (170, 279, 307). 
 
HIV Associated Lymphomas
 Human immunodeficiency virus (HIV)-associated lymphomas are more prevalent 
than PTLD and had an incidence of about 10% during the early stages of the acquired 
immunodeficiency syndrome (AIDS) epidemic amid a larger spectrum of tumor types (19).  
About 50% of these lymphomas are EBV-associated although the association varies with the 
type of tumor (90).  One major category of AIDS lymphomas, which is EBV-positive in 
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about 80% of cases, is very similar to PTLD and appears only in end-stage AIDS.  Most 
lymphomas that present in the central nervous system (CNS) of AIDS patients are of this 
type (182). 
 There are three other categories of HIV-associated lymphomas.  A common small B-
cell lymphoma similar to Burkitt’s that appears in earlier stages of AIDS when the T-cell 
population is mostly unaffected has a 30-40% association with EBV.  This type of lymphoma 
lacks EBNA2 and LMP1 expression (109, 146) and is often one of the first signs of AIDS 
(36, 90).  Large B-cell lymphomas similar to PTLD are also EBNA2 and LMP1 negative.  
They are associated with EBV 30-40% of the time and differ from PTLD in their Bcl-6 
expression (36, 109).  Primary effusion lymphomas, which are consistently positive for 
Kaposi’s sarcoma associated herpesvirus (KSHV), also contain the EBV genome, but only 
EBNA1 expression and trace amounts of LMP1 can be detected (34, 37, 275). 
 
Congenital Immunodeficiencies
 Children who are congenitally immunodeficient are susceptible to EBV-associated 
lymphoproliferative diseases.  Lesions tend to be oligoclonal and show a type III pattern of 
gene expression (73, 279).  Children with common variable immunodeficiency or Wiskott-
Aldrich syndrome are particularly at risk, due to their inability to mount effective T-cell 
control of the viral infection (63). 
 
Oral Hairy Leukoplakia (HLP) 
 Oral Hairy Leukoplakia (HLP) is the only known malignancy caused by an EBV 
permissive infection.  HLP refers to a lesion, usually found in immunocompromised patients, 
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found in the lateral borders of the tongue (102).  The lesion is characterized by thickening of 
the epithelium and shows no viral DNA in the parabasal or basal layers of the epithelium 
underlying the areas where viral replication is taking place (209).  HLP lesions contain no 
episomal DNA and only traces of the EBERs, but do express lytic antigens (93, 218).  
Transformation-competent virus can be detected in the HLP lesions (218).  Interestingly, 
latency-associated viral proteins, EBNA1, EBNA2, and LMP1, can be isolated from the 
upper-layers of the lesion (298). 
 
Burkitt’s Lymphoma (BL) 
 Burkitt’s Lymphoma (BL) can be divided into three categories: endemic, sporadic, 
and AIDS-associated.  Endemic BL is the most common form and is the leading cause of 
childhood cancer in equatorial Africa, as well as coastal New Guinea, with a very high 
incidence (5-10 cases/100,000 per year over the first 15 years of life) and a marked 
geographic distribution determined by climate as well as areas where malaria is holoendemic 
(25, 26, 28, 184, 227) .  Endemic BL tumors are 100% EBV positive (18).  Endemic BL 
usually develops during childhood at extranodal sites in the jaw during molar eruption, in the 
CNS or in the abdomen (237).  Tumors are homogeneous, composed of B-lymphocytes that 
are similar to germinal center B-lymphocytes, and appear to be of monoclonal origin (62, 
233).  BL tumors have one of three reciprocal chromosomal translocations between 
chromosome 8, at or near the c-myc locus and either the Ig heavy-chain locus on 
chromosome 14, or on one of the light-chain loci on chromosomes 2 or 22 (50). 
 Sporadic BL does not have a marked geographical distribution and its association 
with EBV varies wildly from 15-85%.  The incidence of sporadic BL is 50-100 fold lower 
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than endemic BL and the disease peaks at a later age.  Sporadic BL also has a different 
pattern of presentation as it is more frequently associated with an abdominal mass and 
occasionally presents itself as a leukemia (184).  The third form of BL, AIDS associated, was 
discussed previously. 
 BL tumors have a type I pattern of viral gene expression with only EBNA1 
expression and no other viral latency-associated proteins.  It has been hypothesized that 
malaria or HIV infection could induce generalized adenopathy leading to lymphoid 
hyperplasia and expanded germinal centers (237).  The transforming potential of the virus 
may play an important role in the early expansion of the B-cell population, with EBNA2 and 
LMP1 perhaps playing an important role in this early transformation event.  The subsequent 
acquisition of a genetic mutation, such as the aforementioned c-myc translocation, could then 
drive the lesion to a type I pattern of gene expression, as it does not require EBNA2 or LMP1 
(227). 
 
Therapeutic Approaches 
 Pharmacological agents that induce the EBV lytic cycle in conjunction with the 
nucleoside analogue gancyclovir as well as demethylating agents, such as 5-azacytidine, have 
targeted the EBV life-cycle directly (6, 77, 129).  Chemical agents targeting individual EBV 
proteins through single-chain antibodies, RNA interference (RNAi), or by inhibiting the 
signal transduction pathways targeted by the viral proteins (e.g. NFκB, RBP-Jκ) have had 
limited success (31, 75, 144, 226).  Infusion of effector T-cells prepared from the bone 
marrow donor by autologous LCL stimulation and expansion in vitro were highly effective in 
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bone-marrow transplant patients and similar adoptive-transfer approaches are now being 
utilized for PTLD cases as well as for solid-organ transplants (243, 308). 
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OBJECTIVES 
 Latent membrane protein 1 (LMP1) plays a key role in oncogenesis caused by EBV.  
LMP1 is the main EBV oncogene as EBV deleted for LMP1 fails to transform B-
lymphocytes and LMP1 by itself can transform Rat-1 fibroblasts.  LMP1 induces a variety of 
cellular changes including increased motility and inhibition of differentiation.  LMP1 also 
induces a wide variety of signal transduction pathways that affect cellular growth and 
promote survival.  Several LMP1 sequence variants have been isolated from EBV-positive 
tumors.  Interestingly, none of the sequence variants have mutations in the two main LMP1 
signaling domains CTAR1 or CTAR2. 
 The goal of this study is to determine the transforming potential as well as the signal 
transduction potential of the two main signaling domains of LMP1.  A variety of LMP1 
mutants encompassing the carboxyl-terminal tail of LMP1, CTAR1, and CTAR2 as well as 6 
LMP1 sequence variants were examined. 
 
Aim 1. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent 
fibroblast and human fibroblast transformation through activation of PI3K. 
 The roles of CTAR1 and CTAR2 in LMP1-mediated transformation were analyzed.  
The role of CTAR1 and CTAR2 in the activation of the PI3K-Akt signaling pathway as well 
as the role of NFκB and PI3K-Akt signaling in LMP1-mediated transformation were also 
analyzed using chemical inhibitors.  Finally, the role of CTAR1 and CTAR2 in LMP1-
induced aberrant growth of human embryo lung cells was analyzed. 
 
Aim 2. LMP1 strain variants: biological and molecular properties. 
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 The transforming and signal transduction properties of six LMP1 sequence variants 
were analyzed.  The sequence variants were analyzed for their ability to block contact-
inhibited growth and induce anchorage-independent growth in rodent fibroblasts.  The 
sequence variants were also analyzed for their ability to induce cellular migration in human 
keratinocytes and homotypic adhesion in B-lymphocytes.  The activation of the PI3K-Akt 
and NFκB signaling cascades as well as the deregulation of cellular markers involved in cell-
cycle progression were evaluated. 
 
Aim 3. Unique signaling properties of CTAR1 in LMP1-mediated transformation. 
 The role of CTAR1 and its binding cellular targets (TRAF2, TRAF3, and TRAF6) in 
transformation and the induction of signal transduction pathways were analyzed.  The ability 
of dominant negative TRAF2 and TRAF3 to inhibit LMP1-mediated transformation of 
rodent fibroblasts was analyzed.  Furthermore, the transformation and signal transduction 
properties of various LMP1 mutants encompassing the carboxyl-terminal domain were 
analyzed.  The role of the MEK-ERK signaling pathway in LMP1-mediated transformation 
was analyzed. 
 30
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ABSTRACT 
Epstein-Barr Virus (EBV) is a ubiquitous herpesvirus associated with a variety of 
malignancies including nasopharyngeal carcinoma (NPC).  The EBV-encoded latent 
membrane protein 1 (LMP1) is considered the EBV oncogene as it is necessary for EBV-
induced B-lymphocyte transformation and has been shown to transform rodent 
fibroblasts.  LMP1 contains two signaling domains, the carboxy-terminal activating 
region 1 and 2 (CTAR 1 and CTAR2), by which NFκB, phosphatidylinositol 3-kinase 
(PI3K), mitogen-activated protein kinase (MAP kinase), and c-Jun N-terminal kinase 
(JNK) are activated.  In this study, the role of CTAR1 and CTAR2 in LMP1-mediated 
transformation of rodent fibroblasts was analyzed.  CTAR1 was found to be necessary for 
rodent fibroblast transformation whereas CTAR2 was dispensable.  Activation of the 
PI3K pathway in Rat-1 cells by LMP1 and LMP1-CTAR1 in transformed cells resulted 
in phosphorylated Akt and phosphorylated glycogen synthase kinase 3β (GSK3β).  The 
role of PI3K and NFκB activation in LMP1-mediated transformation was further 
analyzed using the chemical inhibitors LY294002 and BAY 11-7085.  LY294002 
inhibited CTAR1-induced focus formation and anchorage-independent growth whereas 
BAY 11-7085 did not inhibit focus formation or anchorage-independent growth.  Similar 
studies in human fibroblasts confirmed that LMP1-CTAR1 also mediates aberrant 
growth, phosphorylation of Akt, and decreased levels of p27.  These findings indicate 
that LMP1-mediated rodent fibroblast transformation is dependent upon activation of 
PI3K and Akt and is independent of activation of NFκB. 
 
INTRODUCTION 
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 Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that is commonly associated 
with a variety of malignancies including nasopharyngeal carcinoma (NPC), 
posttransplant lymphoma, Hodgkin’s disease, and others (20, 35, 44).  The EBV encoded 
latent membrane protein 1 (LMP1) is considered the EBV oncogene as it is essential for 
EBV-induced B-lymphocyte transformation (18) and transforms NIH3T3 and Rat-1 
fibroblasts (2, 20, 43).  LMP1 is frequently expressed in EBV-induced malignancies 
including Hodgkin’s lymphoma and nasopharyngeal carcinoma (11, 44). 
LMP1 contains 386 amino acids, with a short 23 amino acid amino-terminal 
cytoplasmic tail, a transmembrane domain, and a long carboxy-terminal tail that contains 
two signaling domains, carboxy-terminal activating region (CTAR) 1 and 2.  Through 
self clustering in the membrane LMP1 acts as a constitutively active tumor necrosis 
factor receptor (TNFR), mediating signaling by directly interacting with TNFR-
associated factors (TRAF) through CTAR1, as well as by interacting with TNFR-
associated death domain (TRADD) through CTAR2 (15, 31).  Signaling through the 
CTAR domains activates a variety of signaling pathways including NFκB, the mitogen-
activated protein kinase (MAP kinase), c-Jun N-terminal kinase (JNK), and 
phosphatidylinositol 3-kinase (PI3K). (4, 8, 16, 32, 37). 
CTAR1 and CTAR2 have differing effects in the activation of various signaling 
pathways.  CTAR2 is not required for EBV-mediated B-lymphocyte transformation, has 
stronger NFκB activity in reporter assays and can induce JNK signaling (8, 17).  CTAR1 
is necessary for B-lymphocyte transformation by EBV (15).  CTAR1 also has unique 
effects in cellular gene expression as it is required for induction of EGFR and TRAF1 
expression, has recently been shown to activate PI3K (4, 5, 26, 27), decreases levels of 
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p27/KIP (10), and activates distinct forms of NFκB including p50/p50 and p50/p52 
dimers (25, 42). 
In this report the role of CTAR1 and CTAR2 in LMP1-mediated transformation 
in rat and human fibroblasts as well as the role of NFκB and PI3K-signaling in LMP1-
mediated transformation was analyzed.  CTAR1 was required for transformation of Rat-1 
cells as analyzed by loss of contact inhibition as well as anchorage independent growth 
while CTAR2 was dispensable.  CTAR1, but not CTAR2, was required for 
phosphorylation of the PI3K target Akt as well as the Akt kinase target glycogen synthase 
kinase 3β (GSK3β).  Inhibition of PI3K signaling with LY294002 blocked CTAR1-
mediated focus formation and anchorage-independent growth, while the NFκB inhibitor 
BAY 11-7085 did not inhibit focus formation or anchorage-independent growth.  In 
human embryo lung (HEL) fibroblasts CTAR1 was also necessary for inducing aberrant 
growth, phosphorylation of Akt, and decreasing p27 levels.  These data indicate that in 
both human and rat cells signaling from CTAR1 induces the activity of PI3K and that this 
property affects growth regulation in fibroblasts. 
 
RESULTS 
CTAR1 is required for focus formation. 
To determine the contribution of the two primary domains of LMP1 in cellular 
transformation, focus formation in Rat-1 cells was assessed by retroviral transduction 
with vector control (pBabe), HA-tagged full-length LMP1 (LMP1), HA-tagged LMP1 
deleted for CTAR2 (1-231), and HA-tagged LMP1 deleted for CTAR1 (del187-351).  
Cells were analyzed for focus formation (Figure 1) using phase contrast (left and middle 
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panels) and immunofluorescent microscopy for expression of LMP1 using anti-HA 
antibody (right panel).  Focus formation was only observed in cells transduced with 
LMP1 and 1-231 but not pBabe or del187-351 transduced cells.  Examination of the cells 
at low magnification after crystal violet staining indicated that the number of foci were 
relatively equivalent between LMP1 and 1-231 although foci formed by LMP1 were 
larger than those observed with 1-231.  Foci formation was correspondingly decreased by 
serial dilutions of LMP1 and 1-231 (data not shown). 
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Figure 1.  LMP1 and LMP1 CTAR1 block contact-inhibited growth in Rat1 cells.  Rat-1 
fibroblasts were transduced with pBabe, LMP1, 1-231, or del187-351 retrovirus, 
incubated for 10-14 days, stained with crystal violet observed with phase contrast  at 10X 
magnification (left panel), observed for focus formation with phase contrast at 50X 
magnification (center panel) and the same field under immunofluorescence  microscopy 
using anti-HA antibody (right panel). 
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Immunofluorescence staining for LMP1 and 1-231 revealed that expression was 
restricted to foci indicating that all cells that were transduced and expressed LMP1 
formed foci.  However, cells transduced with del187-351 revealed a diffuse staining 
pattern indicating transduction and protein expression without focus formation.  Vector-
transduced cells did not form foci and were negative for staining.  Western blot analysis 
of parallel-transduced cells confirmed expression of LMP1 and LMP1 deletion mutants 
(data not shown).  These data indicate that CTAR1 is necessary for LMP1-mediated 
repression of contact inhibition whereas CTAR2 is dispensable. 
 
CTAR1 induces phosphorylation of the PI3K targets Akt and GSK3β 
As CTAR1 and CTAR2 have been shown to activate distinct signaling events, the 
signaling pathways that could be involved in LMP1-induced transformation were 
analyzed.  Previous studies revealed that of the LMP1 domains, CTAR1 specifically 
activated PI3K (4).  To determine if PI3K signaling was activated by CTAR1 during Rat-
1 transformation, Rat-1 stable cell lines expressing LMP1, 1-231, del187-351, or vector 
control (pBabe) were examined for phosphorylation of the PI3K target Akt and the Akt 
kinase target GSK3β (Figure 2).  Phosphorylation of Akt (Serine 473) was detected with 
LMP1 and at slightly lower levels with LMP1 deleted for CTAR 2 (1-231) but not LMP1 
deleted of CTAR1 (del187-351) or pBabe (Figure 2, 2nd panel).  The activated Akt kinase 
target, GSK3β, was phosphorylated and inactivated in the Rat-1 stable cell lines 
expressing LMP1 and 1-231, but not in pBabe or del187-351, even though LMP1 del187-
351 was expressed at higher levels than LMP1 and 1-231 (Figure 2).  Expression of 
del187-351 did not appear to be toxic as the cells looked healthy and continued to 
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proliferate.  These data indicate that PI3K signaling mediated by CTAR1 in Rat-1 
fibroblasts is able to activate Akt and that such activation leads to the phosphorylation of 
the Akt target GSK3β. 
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Figure 2.  LMP1 and LMP1 CTAR1 induce phosphorylation of Akt and GSK3β.  Cell 
lysates from Rat-1 fibroblast stable cell lines expressing pBabe, LMP1, 1-231, and 
del187-351 were assayed by western blot analysis for expression of the corresponding 
constructs with anti-HA (top panel), as well as phospho and total levels of Akt and 
GSK3β (middle panels), and actin (loading control). 
 
PI3K signaling contributes to LMP1-induced transformation 
LMP1 activates PI3K as well as distinct forms of NFκB from both CTAR1 and 
CTAR2 (4, 25, 42).  To evaluate the contribution of PI3K and NFκB signaling to LMP1-
induced rodent fibroblast transformation, Rat-1 cells were transduced with pBabe, LMP1, 
1-231, or del187-351 and upon reaching 100% confluency were treated with the PI3K 
inhibitor LY294002 (LY), the NFκB inhibitor BAY 11-7085 (BAY 11), or DMSO as 
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vehicle control (Figure 3).  In DMSO treated cells (left column), LMP1 and 1-231 
formed foci while pBabe and del187-351 did not, with 1-231 generally forming smaller 
foci.  Treatment with LY inhibited focus formation in both LMP1 and 1-231 (middle 
columns), indicating that activation of the PI3K signaling pathway is required for LMP1-
induced transformation.  Treatment with BAY 11 (right column), on the other hand, did 
not inhibit focus formation induced by LMP1 or 1-231.  
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Figure 3.  LY294002 but not BAY 11-7085 inhibits LMP1 and LMP1 CTAR1-induced 
focus formation.  Rat-1 cells were transduced with pBabe, LMP1, 1-231, and del187-351, 
incubated for 10-14 days, stained with crystal violet and observed for focus formation at 
10X magnification with phase contrast.  Fresh media containing DMSO, 25µM 
LY294002, or 10µM BAY 11-7085 was replaced every 48 hours. 
 
However, BAY 11 treatment resulted in smaller foci as well as a slightly 
decreased number of foci in comparison to the DMSO-treated cells.  These findings 
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suggest that while LMP1-mediated NFκB activation is not necessary for focus formation 
it likely contributes to enhanced cell growth.  These data indicate that activation of PI3K-
signaling, but not NFκB, is required for focus formation in Rat-1 cells. 
 
CTAR1 induces anchorage independence 
To further evaluate the role of CTAR1 and CTAR2 in LMP1-mediated 
transformation, induction of anchorage independent growth was assessed in soft agar 
growth assays performed with cell lines stably expressing pBabe, LMP1, 1-231, and 
del187-351 (Figure 4).  As in focus formation, cells expressing LMP1 and 1-231 formed 
colonies in soft agar that continued to grow, whereas cells expressing del187-351 and 
pBabe formed small colonies that did not expand (Figure 4A).  The efficiency of 1-231 to 
induce anchorage independent growth appeared equivalent to that of LMP1 as equal 
number of colonies formed from equivalent numbers of cells.  However the 1-231 
colonies were somewhat smaller than those in LMP1-expressing cells.  These data 
confirm that CTAR1 signaling is required and suggest that CTAR2 enhances cell growth 
but is not required for blocking contact inhibition or inducing anchorage independence. 
Colony formation was completely inhibited by LY treatment but not by treatment 
with BAY 11.  To ensure that LY and BAY 11 treatment did not affect expression of 
LMP1, 1-231, and del187-351, western blot analysis was performed on the stable Rat-1 
cell lines (Figure 4B).  Expression levels of LMP1, 1-231 and del187-351 were not 
affected by treatment with DMSO or LY, while BAY 11 appeared to slightly decrease 
del187-351 levels but did not affect LMP1 and 1-231 levels. 
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Figure 4.  Anchorage-independent growth is dependent on LMP1 and LMP1 CTAR1 and 
is inhibited by LY294002.  (A) Rat1 stable cell lines expressing pBabe, LMP1, 1-231 and 
del187-351 were suspended in soft agar and incubated for 14-21 days to assay for 
anchorage-independent growth.  Fresh media containing DMSO, 25µM LY294002, or 
10µM BAY 11-7085 was added to the soft agar suspensions every other day for the 
duration of the time course. (B)  Western blot analysis of Rat1 stables expressing pBabe, 
LMP1, 1-231, and del187-351 using anti-HA to confirm expression when cells were 
treated with DMSO, LY294002, or BAY 11-7085. 
 
To assess the effects of the chemical inhibitors on PI3K and NFκB signaling, 
Rat1 cells expressing pBabe, LMP1, 1-231, or del187-351 were analyzed by 
immunoblotting for phosphorylated Akt, and EMSA for effects on NFκB (Figure 5A).  
LY294002 treatment inhibited Akt phosphorylation (middle 4 lanes) compared to DMSO 
(leftmost 4 lanes) BAY 11 has been shown to inhibit the TNFα-dependent 
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phosphorylation and subsequent degradation of the NFκB negative regulatory subunit 
IκBα (33).  Treatment with BAY 11 treatment (rightmost 4 lanes) reduced the levels of 
phospho-Akt in LMP1, 1-231 and del187-351 but not pBabe.  This effect may reflect that 
Akt is also a target of NFκB activation (24). 
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Figure 5.  LY294002 inhibits Akt phosphorylation and BAY 11-7085 inhibits NFκB 
activation.  (A) Rat-1 stable cell lines expressing pBabe, LMP1, 1-231, and del187-351 
were incubated with DMSO, 25µM LY294002, or 10µM BAY 11-7085 were assayed for 
phosphorylated and total Akt, and β-actin (loading control) by western blot analysis.  (B)  
Stable Rat1 cells expressing pBabe or LMP1 were incubated with DMSO or 10µM BAY 
11-7085 and EMSA was carried out.  Recombinant p50 (left lane) and probe alone (right 
lane) are positive and negative controls respectively.  Long arrows indicate complexes 
supershifted with anti-p65 antibody.  Short arrows indicate the position of p65-containing 
LMP1-induced NFκB complexes. 
To confirm that BAY 11 treatment blocked LMP1-mediated NFκB activation, 
vector control and LMP1 Rat-1 stable cells were analyzed by EMSA using a consensus 
 74
NFκB site (Figure 5B).  Multiple NFκB complexes were detected in the LMP1-
expressing cells that were not present in pBabe or with probe alone.  The two strongest 
complexes, indicated by short arrows, were significantly reduced by addition of p65 
antibody which produced two supershifted complexes, indicated by long arrows.  These 
complexes were significantly reduced by treatment with BAY 11.  These data confirm the 
inhibition of the PI3K and NFκB by treatment with the inhibitors.  Thus, inhibition of 
PI3K with LY blocked Akt phosphorylation and focus formation induced by LMP1 and 
LMP1-CTAR1 while inhibition of NFκB signaling by BAY 11 did not affect focus 
formation induced by LMP1 and LMP1-CTAR1. 
 
LMP1 induces aberrant growth in human fibroblasts 
To determine if LMP1 signaling affects the growth of human cell lines, human 
embryo lung (HEL) fibroblasts were transduced with pBabe, LMP1, 1-231, or del187-
351 (Figure 6).  Transduced cells were maintained in media with serum, stained with 
crystal violet, and observed for morphological changes in LMP1-expressing HEL cells.  
LMP1 and 1-231 induced aberrant growth with large swirled foci, whereas pBabe and 
del187-351 maintained the normal growth pattern (Figure 6A).  Western blot analysis of 
the HEL extracts indicated that LMP1 and 1-231 were expressed at equivalent levels 
(Figure 6). 
Interestingly, expression of del187-351 was decreased compared to that observed 
in Rat1 cells.  This may reflect that del187-351 remains contact inhibited while the LMP1 
and 1-231 transduced cells continue to grow.  Similarly to the effects observed in Rat-1 
cells, LMP1 and 1-231 activated and phosphorylated Akt to higher levels than pBabe and 
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del187-351.  Rat-1 cells expressing LMP1 and 1-231 have been shown to have decreased 
levels of the cyclin dependent kinase inhibitor (cdki) p27/KIP (10).  Expression of LMP1 
and 1-231 in HEL cells also had reduced the p27 protein levels compared to pBabe and 
del187-351 (Figure 6B).  These data also suggest that downregulation of p27 is a factor in 
LMP1-mediated deregulation of cellular growth.  The ability for LMP1 to induce focus 
formation in conjunction with similar effects on signaling and cell cycle regulation in 
Rat-1 and HEL cells suggests that LMP1 affects both rodent and human fibroblast cell 
growth through similar molecular mechanisms. 
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Figure 6.  LMP1 and LMP1 CTAR1 induce focus formation and phosphorylation of Akt 
in human embryo lung fibroblasts.  (A) HEL fibroblasts were transduced with pBabe, 
LMP1, 1-231, and del187-351, incubated for 14-21 days, stained with crystal violet, and 
observed for morphological changes with phase contrast at 15X magnification.  Arrows 
point at LMP1, 1-231 and del187-351.  (B) Transduced HEL fibroblasts were harvested 
and assayed for expression of LMP1 and the two mutants (top two panels), 
phosphorylation and total levels of Akt, p27 levels, and Actin (loading control) by 
western blot analysis. 
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 DISCUSSION 
In this study, LMP1-mediated transformation of rat and human fibroblasts was 
analyzed.  The data indicate that CTAR1 is necessary for focus formation and anchorage-
independent growth whereas CTAR2 is dispensable.  CTAR1 and CTAR2 were 
originally identified by their ability to activate NFκB, although CTAR2 is the stronger 
activator in reporter assays (17, 23, 38).  CTAR1 interacts with several TRAF molecules 
including TRAFs 1, 2, 3, and 5 while CTAR2 interacts with TRADD and receptor-
interacting protein (RIP) and is thought to activate NFκB primarily through TRAF2 (14, 
20, 31).  However, CTAR1 has several unique properties and activates distinct forms of 
NFκB through canonical and noncanonical pathways (1, 22, 28, 39).  Only LMP1 
containing CTAR1 can induce expression of the EGFR, TRAF1, and the ID proteins and 
recent studies indicate that only CTAR1 activates PI3K and inhibits expression of p27 (6, 
10, 17, 25, 27, 28).  Importantly, LMP1 containing CTAR1 is required for transformation 
of B-lymphocytes while CTAR2 is not necessary if the lymphocytes are cultivated on 
fibroblast feeder layers (19). 
A previous study indicated that TRADD binding, mediated by CTAR2, was 
required for transformation of Rat-1 cells and for inducing tumor formation in nude mice 
(12).  However, the study did not analyze the transforming potential of a CTAR1 mutant 
in comparison to the TRADD binding mutant.  It has also been reported that Rat-1 cells 
that are not morphologically transformed can still form tumors in nude mice (36).  
Similarly, the control Rat1 cells used in this study also form tumors (data not shown).  
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The unique ability of CTAR1 to induce focus formation and anchorage 
independent growth required the activation of PI3K.  In contrast, the NFκB inhibitor 
BAY 11-7085 did not inhibit focus formation or colony formation in soft agar, although 
the foci and colonies were generally smaller in 1-231-expressing cells than in LMP1-
expressing cells, suggesting that NFκB activation provides enhanced growth.  Activation 
of NFκB signaling is required for the continued growth of EBV-transformed B-
lymphocytes and inhibition of NFκB signaling with a constitutively active IκB kinase, or 
treatment with BAY 11, induces massive apoptotic death (22).  However, EBV 
transformation of B-lymphocytes reflects immortalization and transformation of primary 
cells.  In contrast, rodent fibroblast transformation identifies altered morphology and 
growth properties in an established cell line.  These findings indicate that activation of 
PI3K is required for the morphologic changes and deregulated growth of fibroblasts 
including loss of contact inhibition and anchorage dependence while activation of NFκB 
can enhance the growth of the deregulated cells.  Thus, deletion of CTAR2 or treatment 
with BAY 11 results in smaller foci. 
The requirement of PI3K-Akt signaling for EBV transformation of B-
lymphocytes is as yet unknown.  However, the data presented in this study indicates that 
activation of PI3K is an important aspect of CTAR1 signaling and is likely also required 
for lymphocyte transformation.  In this study, the transformation properties of LMP1 
were also demonstrated in HEL fibroblasts.  Similarly to Rat-1 cells, in the HEL cells 
full-length LMP1 and CTAR1 but not CTAR2 induced focus formation as well as 
phosphorylation of Akt.  Furthermore, CTAR1 but not CTAR2 decreased the levels of 
the cdki p27/KIP.  The ability for LMP1 to decrease p27 in HEL cells as well as previous 
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data in Rat1 cells indicating decreased p27 levels, suggests that p27 downregulation 
contributes to LMP1-induced transformation (10). 
LMP1 has long been known to associate with vimentin and the cytoskeleton (21).  
This property has been mapped to the CTAR1 domain and mutated forms of CTAR1 that 
do not interact with the TRAF molecules do not associate with the cytoskeleton (13).  
PI3K activation by CTAR1 has also been shown to induce actin stress fiber-formation (4, 
34).  The requirement for CTAR1, the activation of PI3K and the link between CTAR1 
and the cytoskeleton suggests that the morphologic transformation of rodent fibroblasts 
induced by CTAR1 is induced by activation of PI3K and by LMP1 induced interactions 
between TRAFs and the cytoskeleton. 
The PI3K target Akt is known to phosphorylate and inactivate GSK3β (3), 
however the role of LMP1-mediated GSK3β inactivation remains to be elucidated.  The 
EBV latent membrane protein 2A also activates the PI3K-Akt signaling pathway 
resulting in inactivation of GSK3β and subsequent activation of the proto-oncogene β-
catenin in epithelial cells (30).  β-catenin acts by interacting with members of the T-cell 
factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors (41).   
Interestingly, a comparison of EBV positive and negative lymphoid cell lines revealed 
higher levels of cytoplasmic, but not nuclear β-catenin (9).  The presence of high levels 
of cytoplasmic β-catenin but not nuclear levels indicated that in EBV-transformed 
lymphocytes the effects of LMP1 and LMP2 activation on PI3K and phosphorylation of 
GSK3β resulted in β-catenin accumulation but did not affect β-catenin localization.  The 
targets of Akt or GSK3β may be distinct in lymphoid and epithelial cells.  Potential 
differences in the targets of activated Akt in lymphocytes and epithelial cells have also 
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been observed in EBV-associated tumors.  Activated Akt was detected in NPC and in the 
Reed Steinberg cells of Hodgkin's Disease, however, nuclear β-catenin was only detected 
in the malignant epithelial cells of NPC (29).  It is also possible that LMP1 and LMP2 
affect distinct pools of cellular GSK3β.  GSK3β can be phosphorylated by different 
kinases in various intracellular locations and it has been shown that GSK3β 
phosphorylation induced by wnt signaling but not insulin signaling results in activated β-
catenin (7).  Thus, LMP1 and LMP2A may be affecting phosphorylation of different 
pools of GSK3β that results in activation of different signaling pathways in different cell 
backgrounds. 
The induction of focus formation, phosphorylation of Akt, and decreased 
expression of the cdki p27/KIP by LMP1 in HEL cells reveal new properties of CTAR1.  
The downregulation of p27 in Rat1 cells and HEL cells by CTAR1 suggests that 
deregulation of the cell cycle is a component of LMP1-mediated growth transformation 
(10).  Importantly, these findings indicate that the ability of LMP1 to transform rodent 
fibroblasts requires some but not all of the biochemical properties of LMP1.  The full 
effects of LMP1 including activation of NFκB and perhaps other pathways are likely 
required for transformation of primary lymphocytes and the oncogenic properties of 
LMP1 in EBV-associated tumors. 
 
MATERIALS AND METHODS 
Retrovirus production and transduction 
Plasmid constructs expressing HA-tagged full-length LMP1, LMP(1-231), LMP(del187-
351), pBabe, pVSVG, and pGag/Pol and recombinant retrovirus production was 
described previously (10).  Briefly, subconfluent 293T’s were triple-transfected using 
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FuGENE 6 transfection reagent (Roche) according to manufacturer’s directions with 5µg 
pBabe (vector), pBabe-HA-LMP1, pBabe-HA-1-231, or pBabe-HA-del187-351, and 5µg 
pVSV-G and 5µg pGag/Pol expressing plasmids.  Following overnight incubation at 
37°C, media was replaced with fresh media and cells were incubated at 33°C.  The 
following day cell supernatant was centrifuged at 1,000 x g for 5 minutes to remove cell 
debris.  Rat-1 or HEL cells were then transduced with clarified supernatant with 4µg/ml 
polybrene overnight. 
 
Cell culture and stable cell lines 
Rat-1 fibroblasts and human embryo kidney 293T’s were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with heat inactivated 10% fetal bovine 
serum (FBS) and antibiotic/antimycotic (GIBCO).  Human Embryo Lung 299 (HEL) 
cells were maintained in Minimum Essential Medium (MEM) alpha and the additives 
mentioned for DMEM as well as non-essential amino acids.  Rat-1 stable cell lines 
expressing full-length LMP1, LMP(1-231), LMP(del187-351), or vector control (pBabe) 
were established by transduction with recombinant retrovirus followed by selection with 
5µg/ml puromycin (SIGMA). 
 
Western blotting and densitometry analysis 
Cell lines were grown to confluency and harvested as described previously (10).  Briefly, 
post harvesting, cells were washed with ice-cold phosphate buffered saline (PBS, 
GIBCO), centrifuged at 1,000 x g, lysed with RIPA buffer (20mM Tris-HCl pH 7.5, 
150mM NaCl, 1mM EDTA, 1% NP40, 0.1% SDS, 0.1% deoxycholate, protease and 
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phosphatase inhibitors).  Lysates were clarified by centrifugation and protein 
concentration was determined using Bio-Rad DC protein assay system.  Lysates were 
boiled in SDS-sample buffer and 25µg of protein were separated by SDS-PAGE and 
transferred to Optitran® (Schleicher & Schuell) for western blot analysis.  Primary 
antibodies used include β-actin (Santa Cruz), CS1-4 (DAKO), HA-probe (Santa Cruz); 
phospho-Akt (Ser 473), total Akt, phospho-GSK3β (Ser 9), p27 (Calbiochem); total 
GSK3 (Upstate Biotechnology).  Bound proteins were detected with horseradish 
peroxidase-conjugated secondary antibodies (Amersham Parmacia and Dako) and Pierce 
Supersignal West Pico System followed by exposure to film. 
 
Immunofluorescent labeling and phase contrast microscopy 
Rat-1 cells stably expressing LMP1, 1-231, del187-351 or pBabe were seeded in 6-well 
plates and maintained from 10-14 days, changing the media every other day, under 
puromycin selection for foci formation.  Wells were then washed once with PBS, fixed 
with methanol for 5 minutes at room temperature, and washed three times with PBS.  
Cells were blocked for 20 minutes with PBS containing 20% normal goat serum (NGS), 
incubated with primary antibody in PBS-20% NGS for 1 hour, washed 3 times with PBS, 
incubated with rhodamine-conjugated secondary (Jackson Laboratories) in PBS-20% 
NGS for 1 hour, and washed 3 times with PBS.  Stained cells were examined with phase 
contrast and fluorescence microscopy. 
 
Focus formation and soft agars 
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Subconfluent Rat-1 or HEL cells were transduced with recombinant retrovirus in 6-well 
plates overnight.  Cells were then maintained by changing the media every other day for 
10-14 days.  To assay focus formation in the presence of chemical inhibitors, stable cell 
lines were seeded in 6-well plates.  Upon cells reaching confluency, and every other day 
thereafter, fresh media containing 25µM LY294002 (Calbiochem), 10µM BAY 11-7085 
(Calbiochem) or vehicle control (dimethyl sulphoxide, DMSO, Sigma) used at 1:1000 
was added to the cells.  Cells were then stained with 1% crystal violet in 50% ethanol and 
imaged with a stereo microscope.  Soft agars were carried out as described previously 
(40).  Briefly, Bacto agar medium (1ml 5% Bacto Agar and 9ml DMEM with 10% FBS 
and antibiotic/antimycotic) was poured into a 12-well plate and allowed to solidify.  
1.0x104 cells/well were resuspended in Bacto agar medium, overlaid the initial layer of 
Bacto agar medium and allowed to solidify.  The media changed every other day with 
containing 1:1000 DMSO, 25 µM LY294002, or 10µM BAY 11-7085 was changed 
every other.  Cells were then imaged by phase contrast or a dissecting microscope. 
 
Electrophoretic mobility shift assay (EMSA) 
Nuclear fractionations and EMSAs were performed as previously described (42).  Rat-1 
cells stably transduced with pBABE or LMP1 retrovirus were treated with Bay11-7085 
(10µM) or vehicle control (DMSO) for 24 hours and fractionated.  DNA-protein 
complexes were formed by mixing 10µg of nuclear extract with 100,000 counts of the 
UV21 double-stranded oligonucleotide probe 
(CAGGGCTGGGGATTCCCCATCTCCCACAGTTTCACTTC), which is based on the 
H-2Kb gene containing a consensus NFκB binding site (underlined) labeled with [α-32P] 
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dCTP.  After allowing the complexes to form for 15 minutes at room temperature, DNA-
protein complexes were resolved on 5% PAGE and imaged using a PhosphorImager 
(Molecular Dynamics).  Probe alone and positive control, recombinant p50 (Promega), 
were included and p65 containing complexes were determined by supershifting with anti-
p65 antibody (Rockland). 
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ABSTRACT 
The ubiquitous herpesvirus Epstein-Barr virus (EBV) is linked to the development 
of several malignancies including nasopharyngeal carcinoma.  Latent membrane protein 
1 (LMP1) is considered the EBV oncogene as it is necessary for EBV-induced 
transformation of B-lymphocytes and is able to transform Rat-1 fibroblasts.  LMP1 can 
activate a wide array of signaling pathways including PI3K-Akt and NFκB.  Seven 
sequence variants of LMP1; Alaskan, B95.8, China 1, China 2, Med+, Med-, and NC; 
have been identified and individuals are infected with multiple variants.  The frequency 
of detection of these variants differs in various EBV-associated malignancies from 
different geographic regions.  In this study, the biological and signaling properties of the 
LMP1 variants have been characterized.  All of the LMP1 variants transformed Rat-1 
fibroblasts, induced increased motility of HFK cells, and induced increased homotypic 
adhesion of BJAB cells.  While all the variants activated the PI3K-Akt signaling pathway 
to a similar extent, the Alaskan, China 1, and Med+ variants had limited binding to the 
E3 ubiquitin ligase component HOS and had slightly enhanced NFκB signaling.  These 
findings indicate that the signature amino acid changes of the LMP1 variants do not 
hinder or enhance their in vitro transforming potential or affect their signaling properties. 
 
INTRODUCTION 
Epstein-Barr Virus is a ubiquitous herpesvirus that infects greater than 90% of the world's 
population.  EBV infection is associated with a wide array of malignancies including 
nasopharyngeal carcinoma (NPC), Hodgkin lymphoma (HD), post-transplant lymphoma, 
Hairy Leukoplakia (HLP), Burkitt’s lymphoma, and others (24, 45, 62).  EBV primary 
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infection is usually asymptomatic, although at times it results in the benign 
lymphoproliferative disease infectious mononucleosis (40).  Viral reactivation may occur 
in latently infected memory B cells and virus can frequently be detected in saliva (3, 49, 
50).  Viral infection is considered latent in EBV malignancies and in NPC and HD viral 
expression is restricted to EBNA1, LMP1, LMP2 and the EBER and BART RNAs (24). 
Latent membrane protein 1 (LMP1) is considered the EBV oncogene as it 
transforms NIH3T3 and Rat-1 fibroblasts.  It is essential for EBV-induced B-lymphocyte 
transformation (22, 24, 32, 52, 58) and is frequently expressed in EBV-malignancies (15, 
62).  LMP1 consists of 386 amino acids with a short 23 amino-terminal cytoplasmic tail, 
6 transmembrane domains, and a long carboxyl-terminal tail that contains the two 
signaling domains carboxyl-terminal activating region (CTAR) 1 and 2.  LMP1 self-
associates in the plasma membrane due to its hydrophobic transmembrane domains and 
thus acts as a constitutively active growth factor receptor that does not require a ligand 
for its activation.  The tumor necrosis factor receptor (TNFR)-associated factors (TRAF) 
associates with LMP1 which signals similarly to CD40 and the type II TNFR (9, 21, 39).  
As such, LMP1 activates a wide array of signaling pathways through CTAR1 and 
CTAR2, including NFκB, mitogen-activated protein kinase (MAPK), c-Jun N-terminal 
kinase (JNK), and phosphatidylinositol 3-kinase (PI3K)-Akt pathways (7, 12, 14, 20, 32, 
42, 46).  LMP1 also induces the deregulation of the cell cycle through manipulation of 
various cell cycle regulatory molecules including the cyclin dependent kinase inhibitor 
(cdki) p27Kip1, p16, inhibitor of differentiation (Id) 1 and 3, retinoblastoma (Rb), and 
cyclin dependent kinase 2 (CDK2) (14, 27, 41). 
 93
Six LMP1 sequence variants, termed Alaskan, China 1, China 2, Mediterranean+ 
(Med+), Mediterranean- (Med-), North Carolina (NC) have been isolated from clinical 
specimens (10, 35).  These variants are distinguished by various signature amino acid 
changes from the prototypic LMP1 (B95.8), although changes are not found in CTAR1 or 
CTAR2.  In addition China 1 and Med+ have a 10 amino acid deletion between CTAR1 
and CTAR2 (10).  Although this 10 amino acid deletion has been linked to augmented 
transforming ability (28), several studies have indicated that LMP1-contained CTAR1 is 
essential and sufficient for Rat-1 fibroblast and Madin-Darby Canine Kidney (MDCK) 
cell transformation (25, 32).  NFκB activation and the transforming properties of the B95, 
Med+, and Cao variants have been compared (4, 6, 16, 17, 29, 34).  A slight enhancement 
in the ability of the CAO variant, which is most similar to China 1, and the Med+ variant 
to induce NFκB signaling was mapped to the transmembrane domains.  LMP1 also 
interacts with the E3 ubiquitin ligase component Homologue of Slimb (HOS), a member 
of the β-TrCP/Fbw1 subfamily of F box proteins, which regulates the ubiquitin-
dependent destruction of IκBα and β-catenin (34, 47, 53, 60). 
Several studies have revealed that individuals are infected with multiple EBV 
variants and that the LMP1 variants differ in abundance between throat washings and 
peripheral blood and their detection and abundance varies over time (49-51).  It is 
possible that these differences in abundance and detection reflect different biological 
properties or cellular tropism.  Recently, computational analysis of the variants revealed 
key amino acid changes in potential Human Leukocyte Antigen (HLA)-restricted 
epitopes, suggesting a potential immune-modulated selection mechanism (11).  Although 
all variants have been detected in various malignancies, the CAO/China 1 LMP1 variant 
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is significantly more prevalent in NPC tumors from the southern endemic region of China 
and is predicted to not be presented by individuals who are A2 or A24, the most common 
HLA types found in patients with NPC from this region (11). 
In this report, the biologic properties of the LMP1 variants were characterized 
through their ability to transform Rat-1 fibroblasts, affect epithelial cell motility, and 
induce homotypic adhesion of B lymphocytes.  The LMP1 variants were also evaluated 
for their potential to activate the PI3K-Akt and NFκB signaling pathways as well as their 
ability to alter cell cycle markers that have been associated with G1/S phase progression.  
All the variants were capable of transforming Rat-1 fibroblasts as measured by blockage 
of contact-inhibited and anchorage-independent growth, and induced homotypic adhesion 
in BJAB cells.  The PI3K-Akt signaling cascade was activated by all variants and this 
activation was necessary for LMP1-induced Rat-1 transformation.  Changes in cellular 
markers that are frequently associated with cell cycle deregulation were also induced by 
all variants.  Finally, the Alaskan, China 1, and Med+ variants had increased NFκB 
reporter activity compared to the other variants in conjunction with decreased binding to 
HOS.  These similarities in biologic and molecular properties suggest that all of the 
variants have equal pathologic potential, in agreement with their detection in multiple 
types of cancer.   
 
MATERIALS AND METHODS 
Plasmids.  LMP1 variants were subcloned into the myc-tagged expression vector 
M3-pcDNA3-Hygromycin (26) from pGEM32.  The Alaskan, China 1, and China 2 
variants were PCR amplified with the 5’ primer 
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(CGACGGATCCATATGGAACGCGACCT) and the 3’ primer 
(ATCACGAGTCTAGAAATGTGGCTTTTCAGCCTAG) followed by restriction 
enzyme digestion and insertion into the BamHI and XbaI sites of M3-pcDNA3-Hyg.  The 
B95.8, Med+, Med-, and NC variants were PCR amplified with the 5’ primer 
(CGACGGATCCATATGGAACACGACCT) and the 3’ primer 
(ATCACGAGTCTAGAAATGTGGCTTTTCAGCCTAG) followed by the above-
described cloning procedure. 
LMP1 variants were then subcloned into the pBabe-puromycin (pBabe) vector 
without the myc-tag but adding an HA tag.  B95.8, Med+ and NC were PCR amplified 
with LMP1-HA5’ and LMP1-3’ (16).  NCdel93C was isolated during the cloning of NC 
as a spontaneous mutation, glutamine to stop, resulting in the deletion of the last 93 
amino acids of NC.  Med- was PCR amplified with LMP1-HA5’ and LMP1-SAL3’ 
(ATCACGAGGTCGACAATGTGGCTTTTCAGCCTAGAC).  China 1 and China 2 
were PCR amplified with LMP1-C12AL5’ 
(GCCGGATCCATGGCTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGTG
GTCATATGGAACGCGACCTTGAGAGG) and LMP1-3’.  Alaskan was PCR amplified 
with LMP1-C12AL5’ and LMP1-SAL3’.  PCR amplification was followed by restriction 
enzyme digestion and insertion into the BamHI and EcoRI (B95.8, China 1, China 2, 
Med+, NC and NCdel93C) or BamHI and SalI (Alaska and Med-) sites of pBabe. 
The HA-tagged pcDNA3-Homologue of Slimb (HOS) plasmid was a gift of Serge 
Fuchs, University of Pennsylvania (53). 
Retrovirus production and transduction.  Retrovirus production was carried 
out as described previously (14).  Briefly, subconfluent 293T cells were triple transfected 
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using FuGENE 6 (Roche) according to manufacturer’s directions with 5µg of pBabe or 
each of the pBabe-HA-tagged LMP1 variants, 5µg pVSVG, and 5µg pGag/Pol.  
Following overnight incubation at 37°C media was replaced with fresh media, DMEM 
for BJAB and Rat-1, and Keratinocyte-SFM medium following a gentle wash with PBS 
for HFK, and cells were incubated at 33°C overnight.  Cell supernatant containing the 
retrovirus was then cleared of cellular debris through centrifugation at 1000 g for 5 min.  
Rat-1 or HFK were then transduced with clarified supernatant with 4µg/ml polybrene 
overnight.  BJAB cells were transduced through spinoculation of 3.0x105 cells with 1ml 
of retrovirus and 4µg/ml polybrene for 3 hours at 2000 g followed by removal of spent 
media and resuspension of pellet in RPMI. 
Cell culture and stable cell lines.  Rat-1 fibroblasts (Rat-1) and human embryo 
kidney 293T (293T) cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, GIBCO) supplemented with heat-inactivated 10% fetal bovine serum (FBS, 
Sigma) and antibiotic/antimycotic (GIBCO).  Rat-1 cells were prepared fresh for each 
experiment and were maintained for no more than four passages.  Human foreskin 
keratinocyte (HFK) cells, immortalized with hTERT, were maintained in Keratinocyte-
SFM (GIBCO) medium supplemented with 15ng bovine pituitary extract (BPE, GIBCO), 
100ng epidermal growth factor (EGF, GIBCO) and antibiotic/antimycotic.  BJAB cells 
were maintained in RPMI 1640 (GIBCO) medium supplemented with 10% FBS and 
antibiotic/antimycotic.  Stable cell lines expressing pBabe or the variants in pBabe were 
established by transduction with recombinant retrovirus followed by selection with 
5µg/ml puromycin (Sigma) for Rat-1 cells and 2.5 µg/ml puromycin for HFK and BJAB 
cells. 
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Homotypic adhesion assay.  BJAB cells were transduced by spinoculation, 
placed under puromycin selection followed by separation though LSM Lymphocyte 
Separation Medium (ICN) gradient and amplification of live cells under puromycin 
selection.  Equal cell numbers (~1.0x104 cells/ml) were plated in a 6 well plate and 
observed every 24 hours for clumping with phase contrast microscopy. 
Cell harvesting and western blotting.  Cell lines were grown to confluency and 
harvested as described previously (14).  Briefly, postharvesting, cells were washed with 
ice-cold phosphate buffered saline (PBS, GIBCO), centrifuged at 1000 g, lysed with 
RIPA buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1% NP40, 0.1% SDS, 
0.1% deoxycholate, 0.5mM phenylmethylsulfonyl fluoride (PMSF), 1mM Na3VO4, and 
protease and phosphatase inhibitors (SIGMA)).  Lysates were clarified by centrifugation 
and protein concentration was determined using Bio-Rad DC protein assay system.  
Lysates were boiled in SDS sample buffer for 5 min. and 12.5-25µg of protein were 
separated by SDS-PAGE and transferred to an Optitran® membrane (Schleicher and 
Schuell) for western blot analysis and efficient transfer was measured with Ponceau S 
staining (DiaSys Europe Ltd.).  Primary antibodies used include HA-probe (Santa Cruz), 
c-myc tag (Santa Cruz), β-catenin (BD Biosciences), CS1-4 (Dako), LMP1 Rat 
monoclonal pool (Ascenion; CAO 7E10, CAO 8G3, LMP 1G6 and CAO 7G8), β-Actin 
(Santa Cruz), total GSK3 (Upstate Biotechnology), p27/KIP (Calbiochem), Id1 (Z8, 
Santa Cruz), phospho-Rb (T373, Oncogene), Rb (BD Biosciences), p21/WAF 
(Oncogene), CDK2 (BD Biosciences), phospho-CDK2 (T160), phospho-Akt (Ser473), 
total Akt, phospho-GSK3β (Ser9), phospho-mTOR (Ser2448), phospho-PTEN (Ser380), 
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phospho-mTOR (Ser2448), total IκBα,  total PTEN, E-cadherin (Cell Signaling).  
Densitometry analysis was done using Image J software. 
Focus formation and soft agars.  Subconfluent Rat-1 cells were transduced with 
recombinant retrovirus in six-well plates overnight.  Cells were then maintained by 
changing the media every other day for 10-14 days.  To assay focus formation in the 
presence of LY294002 (LY, Calbiochem), stable cell lines were established as mentioned 
previously and seeded in 6-well plates.  Upon reaching confluency, and every day 
thereafter for 10-14 days, fresh media containing 25µM LY or vehicle control (DMSO, 
Sigma) used at 1:1000 was added to the cells.  Cells were then stained with 1% crystal 
violet in 50% ethanol and imaged with a stereomicroscope.  Soft agars were carried out 
as described previously (32, 48). Briefly, Bacto agar medium (5% Bacto agar into 
DMEM with 10% FBS and antibiotic/antimycotic to a 0.5% final concentration of Bacto 
agar) was poured into a twelve-well plate and allowed to solidify.  A total of 1.0x104 
cells/well were resuspended in Bacto agar medium, overlaid the initial layer of Bacto 
agar medium and allowed to solidify.  Media was added on top of the solidified Bacto 
agar medium and changed every other day for 14-21 days.  Cells were imaged with a 
phase contrast microscope. 
Migration assay.  Stable HFK cells were established as mentioned previously 
and seeded in six-well plates.  Upon reaching confluency, cells were washed with PBS 
and the media was replaced with Keratinocyte-SFM media without EGF and BPE for 24-
48 hours.  Cells were then scratched with a 200µl tip, the media was immediately 
changed followed by incubation at 37°C and imaged at 24 and 48 hours with phase 
contrast microscopy.  Prior to imaging cell media was replaced to remove cell debris. 
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Immunofluorescent labeling.  Rat-1 cells expressing pBabe and pBabe-HA-
tagged LMP1 variants were maintained in a six well plate for 10-14 days changing the 
media every other day.  Cells were then washed once with PBS, fixed with methanol for 
5 min at room temperature and washed 3 times with PBS.  Cells were blocked for 20 min 
with PBS containing 20% normal goat serum (NGS, Jackson Laboratories), incubated 
with primary antibody in PBS-20% NGS for 1 h, washed three times with PBS, incubated 
with rhodamine-conjugated secondary (Jackson Laboratories) in PBS-20% NGS for 1h, 
and washed three times with PBS.  Stained cells were observed with phase contrast and 
fluorescence microscopy. 
Co-immunoprecipitations and NFκB Reporter.  HA-tagged HOS and myc-
tagged LMP1 variants were immunoprecipitated using Pierce Mammalian ProFound HA 
and c-myc Tag Co-IP Kits as indicated by the manufacturer’s directions.  Briefly, 293T 
cells were transfected with HA-tagged HOS and either pcDNA3 or the myc-tagged 
LMP1 variants.  Cells were harvested 48 hours post transfection with RIPA buffer and 
protein concentration was determined as mentioned previously.  IPs were carried out with 
500µg of protein and 10µl of the provided myc- or HA-agarose slurry with overnight 
nutation at 4°C followed by the manufacturer’s instructions.  Co-IPs were then separated 
in an SDS-PAGE and western blots were carried out as previously mentioned. 
NFκB reporter assays were carried out by transfecting subconfluent 293T cells in 
a 12-well plate with Fugene 6 containing 0.2µg pcDNA3 (vector control) or 0.2µg 
pcDNA3-LMP1 variants, 0.2µg pRL-SV40 (Promega), and 0.2µg pGL3-Basic or 0.2µg 
pGL3-3NFκB (3κB), a gift from Albert Baldwin’s lab (43).  Cells were harvested 36-48 
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hours post transfection and luciferase activity was determined as mentioned previously 
(14). 
Statistical Analysis.  P values were calculated using a Tukey-Krammer multiple 
comparison test using the triplicate relative luciferase values from the NFκB reporter.  
Statistical analysis was done using GraphPad Instat 3 software.   
 
RESULTS 
LMP1 variants transform Rat-1 fibroblasts.  LMP1 is considered the EBV 
oncogene as it blocks contact-inhibited growth and induces anchorage independent 
growth in Rat-1 fibroblasts (14, 32, 58).  To determine the ability of the LMP1 variants to 
block contact inhibited growth, Rat-1 fibroblasts were transduced with pBabe and pBabe-
HA-tagged variants (Alaskan, B95.8, China 1, China 2, Med+, Med-, NC, and 
NCdel93C).  14 days post transduction cells were analyzed for focus formation and 
expression of the variants by phase contrast and immunofluorescent microscopy (Fig. 1).  
Whereas pBabe did not induce focus formation, all of the LMP1 variants induced foci.  
NCdel93C, which is deleted for CTAR2 but not CTAR1, also induced foci confirming 
the previous finding that CTAR1 but not CTAR2 is necessary for focus formation (32).  
Immunofluorescent microscopy using the LMP1-specific antibody CS1-4 revealed that 
expression of the variants was restricted to the foci indicating that all cells that expressed 
LMP1 formed foci.  Immunofluorescent staining for the Alaskan variant is not included 
as the CS1-4 antibody does not recognize the Alaskan variant.  There was some 
variability in the size and morphology of the foci induced by all the LMP1 variants but all 
the LMP1 variants formed large and small foci of similar morphology.  Equivalent 
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amounts of DNA used to make retrovirus and serial dilutions of the retrovirus for each 
variant yielded similar numbers of foci (data not shown).  This data suggest that all 
variants are equally efficient in focus formation. 
 
Med +
Med -
NC
NCdel93C
pBabe
B958
China 1
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Alaskan
 
Figure 1.  LMP1 variants block contact inhibited growth of Rat-1 cells.  Rat-1 fibroblasts 
were transduced with pBabe and pBabe-LMP1 variants, maintained for 10-14 days in full 
serum, fixed and stained with the anti-LMP1 antibody CS1-4, followed by imaging with 
phase contrast and immunofluorescent microscopy for focus formation.  Alaskan 
immunofluorescent staining is not provided. 
 
To further determine the transforming ability of the LMP1 variants, Rat-1 cells 
stably expressing the LMP1 variants were assayed for anchorage-independent growth by 
growth in soft agar.  Similarly to that observed with focus formation, all LMP1 variants 
were able to induce anchorage-independent growth (Fig. 2).  Equivalent numbers of cells 
stably expressing the variants induced equal number of colonies of varying size and 
morphology indicating that all LMP1 variants are able to induce anchorage-independent 
 102
growth with equivalent efficiency.  The size variation between colonies may be due to 
variable LMP1 expression within each colony.  These data in conjunction with the ability 
of all the variants to block contact-inhibited growth suggest that the signature amino acid 
changes in the LMP1 variants do not impede or enhance their transforming potential. 
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Figure 2.  Anchorage-independent growth of Rat-1 fibroblasts is induced by LMP1 
variants.  Rat-1 cells stably expressing the LMP1 variants or vector control (pBabe) were 
resuspended in soft-agar and maintained for 21 days followed by imaging with phase 
contrast microscopy for anchorage-independent growth. 
 
LMP1 variants induce increased motility.  It has been previously shown that 
expression of LMP1 in the nasopharyngeal carcinoma cell line NP69 that expresses SV40 
T antigen or the MDCK canine cell line induces cellular motility (25, 29).  In addition 
LMP1 induces actin stress-fiber and filopodia formation (44). To determine the ability of 
the LMP1 variants to induce motility in normal human epithelial cells, a wound heal 
scratch assay was performed using telomerase immortalized human keratinocytes.  
Monolayers of HFK cells stably expressing the LMP1 variants were serum starved, 
scratched and observed for their ability to migrate into the wound at 24 and 48 hours post 
scratch (Fig. 3).  The scratch boundaries are delineated with white lines at the 48 hour 
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time-point.  Although there were small differences in the rate of migration between the 
variants, all variants were able to migrate at a faster rate than the vector control cells 
(pBabe).  The NCdel93C-expressing cells also induced migration into the wound, 
confirming the role of CTAR1 in LMP1-mediated cell motility. 
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Figure 3.  LMP1 variants increase motility of HFK cells.  Monolayers of HFK cells 
stably expressing the LMP1 variants or vector control (pBabe) were scratched and 
assayed for increased motility 24 and 48 hours post scratch by phase contrast microscopy.  
White lines delineate approximate location of scratch boundary. 
 
LMP1 variants activate the PI3K-Akt signaling pathway.  A recent study 
indicated that LMP1 transformation of Rat-1 fibroblasts is dependent on activation of the 
PI3K-Akt pathway (7, 32).  To assess the ability of the LMP1 strains to activate Akt, 
phosphorylation of Akt as well as various targets of Akt was assessed in the stably LMP1 
expressing Rat-1 cells analyzed in Figure 2 (Fig. 4A).  Although the total levels of Akt 
were not changed, variable levels above vector control of activated Akt were detected 
with all the LMP1 variants (Fig. 4B).  Increased phosphorylation of the Akt target 
GSK3β was also detected with all the LMP1 variants (Fig. 4A).  Interestingly, 
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phosphorylation of another Akt target, mTOR (mammalian Target of Rapamycin), was 
not affected.  Total Akt and total GSK3 blots in conjunction with Ponceau S staining and 
an actin blot (not shown) confirmed equal loading on all lanes.  These findings indicate 
that activation of Akt by LMP1 affects a subset of Akt-regulated pathways. 
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Figure 4.  Activation of the PI3K-Akt signaling pathway by LMP1 variants.  (A) LMP1 
variants and vector control (pBabe) expressed stably in Rat-1 cells were assayed for 
LMP1 expression with CS1-4 and HA antibodies (asterisks identify LMP1-specific 
bands), phosphorylated and total Akt and GSK3β, PTEN, mTOR and total E-cadherin by 
western blot analysis.  Equal protein loading was confirmed with Ponceau S staining and 
an actin western blot (not shown). (B) Quantitative analysis of LMP1 (white bars), 
phosphorylated Akt (checkered bars), phosphorylated GSK3β (striped bars), and E-
Cadherin (black bars) protein levels.  LMP1 levels were normalized to B95.8 whereas 
phospho-Akt, phospho-GSK3β, and E-cadherin levels were normalized to pBabe. 
 
Expression of the LMP1 variants was assessed using a polyclonal antibody to HA 
and the CS1-4 monoclonal antibody pool (Fig. 4A).  Detection by HA suggested similar 
levels of expression of Alaskan, B95.8, China 1 and Med+ and lower levels of China 2, 
Med -, and NC (marked by an asterisk in Fig. 4A).  In contrast, detection by CS1-4 
suggested that the B95.8, China 1, and China 2 were expressed at very high levels with 
low levels of Med- and NC and nearly undetectable Med+.  Alaskan is not detected by 
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CS1-4.   These differences clearly indicate differences for the affinity of CS1-4 antibody 
for the different LMP1 variants.  Surprisingly, the HA epitope tag was apparently 
recognized with differing affinities for the tagged variants. CS1-4 also detects consistent 
cleavage products for each LMP1 variant that are not observed with HA.  This suggests 
that there are differences in preferred proteolytic cleavage sites between the variants that 
eliminate the amino terminal end of LMP1 thus removing the HA tag.  These differences 
in cleavage products may account for the differences in the detection of the LMP1 
variants by the HA antibody. 
The clear differences in reactivity to the antibodies indicate that the expression 
levels of the LMP1 variants cannot be directly compared.  However, densitometry of 
LMP1 expression levels as well as total levels of phospho-Akt, phospho-GSK3β, and E-
cadherin was performed (Fig. 4B).  LMP1 expression was normalized to the B95.8 
variant, using the HA western blot data, whereas the other markers were normalized to 
vector control (pBabe).  Expression of the LMP1 variants as estimated by HA reactivity 
ranged from 19% for China 2 to 117% for Med+ compared to the B95.8 variant (white 
bars).  Akt phosphorylation was increased from 127% to 223% of control (checkered 
bars).  In Alaskan, B95.8, China 1, and Med+, which seem to be roughly equally 
expressed based on HA reactivity, normalization of the induction of Akt to LMP1 
expression ranged from 1.4 to 1.9 fold.   In cells expressing China 2, Med-, and NC, 
which seem to be poorly detected by the HA antibody, normalization to LMP1 suggested 
induction that ranged from 4.5 to 9.2 fold.   Phosphorylation of GSK3β ranged from 
257% to 453% of vector control and normalization to LMP1 indicated fold increases 
from 2.9 to 3.8 for variants detected similarly by anti-HA and from 4.5 to 9.2 for the 
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poorly detected variants.  The disproportionately high ratios for the China 1, Med-, and 
NC variants also suggest that the expression levels of LMP1 are underestimated for these 
variants. 
It has been previously reported that LMP1 induces the methylation of the E-
cadherin promoter resulting in the overall decrease of E-cadherin protein levels in LMP1-
expressing NPC cell lines (56, 57).  To determine the effects of the LMP1 variants on E-
cadherin expression western blot analysis was performed with Rat-1 cells stably 
expressing the LMP1 variants (Fig. 4A).  E-cadherin levels were decreased with all 
variants and detected at levels from 19% in the Med- variant to 46% in the B95.8 variant 
as compared to pBabe (black bars).  Similarly to Akt and GSK3β, the overall reduction of 
E-cadherin levels did not correlate with the estimated expression levels of the LMP1 
variants as determined by HA.  The China 1 and China 2 variants, which are very 
differently detected by anti-HA, were expressed at similar levels as detected by CS1-4 
and the stable cell lines expressing China 1 and China 2 had 40% and 44% of the E-
cadherin expressed in the pBabe control.  These data suggest that they have equivalent 
effects on E-cadherin.   
The PTEN phosphatase regulates PI3K-Akt signaling through its ability to 
regulate the phosphorylation status of phosphoinositides.  Loss of function mutations of 
PTEN have been identified with several cancers, including endometrial carcinomas and 
lymphomas (31).  To determine if the activation of PI3K by LMP1 is mediated by 
affecting PTEN expression or its activation status, western blot analysis for the 
phosphorylated, inactive form of PTEN as well as total levels of PTEN was performed 
(Fig. 4A).  Expression of the LMP1 variants did not affect the levels of phosphorylated 
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PTEN with slight increases in total PTEN.  These results suggest that PI3K-Akt 
activation by LMP1 is not mediated by PTEN inactivation or reduced PTEN protein 
levels.  
 
These findings indicate that all LMP1 variants can activate the PI3K-Akt signaling 
pathway as well as reduce E-cadherin protein levels.  However, none of the variants alter 
the activation status of mTOR or PTEN. 
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Figure 5.  LY294002 blocks LMP1-induced focus formation.  Rat-1 cells stably 
expressing vector control (pBabe) or the LMP1 variants were seeded in 6-well plates and 
maintained for 10-14 days in media with the PI3K-inhibor LY294002 or vehicle control 
(DMSO), stained with crystal violet, and observed for focus formation with phase 
contrast microscopy. 
 
LY294002 blocks focus formation by LMP1 variants.  A previous study 
indicated that transformation of Rat-1 fibroblasts is dependent on PI3K-Akt activation 
(32).  To determine if the requirement of the LMP1 variants to block contact inhibited 
growth is dependent on the PI3K-Akt signaling pathway, Rat-1 cells stably expressing 
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the LMP1 variants were treated with vehicle control (DMSO) or the PI3K chemical 
inhibitor LY294002 (LY) for 10-14 days and were observed for focus formation (Fig. 5).  
As previously observed for the B95.8 strain of LMP1 (32), LY treatment abolished focus 
formation for all LMP1 variants indicating that activation of the PI3K-Akt pathway is 
required to suppress contact inhibition.  LMP1 expression and inhibition of PI3K-Akt 
signaling, through analysis of phosphorylated Akt levels, was confirmed by western blot 
analysis (data not shown). 
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Figure 6.  LMP1 variants regulate cell cycle progression protein markers.  (A) Rat-1 cells 
stably expressing pBabe or the LMP1 variants were assayed for LMP1 expression 
(asterisk delineates LMP1 variant), p27 and Id1 protein levels by western blot analysis.  
Equal loading was confirmed with an actin western blot. (B) Quantitative analysis of 
LMP1 (white bars), p27 (black bars), and Id1 (striped bars) protein levels.  LMP1 
expression was normalized to B95.8 whereas p27 and Id1 levels were normalized to 
pBabe.  (C)  HFK cells stably expressing pBabe or the LMP1 variants were assayed for 
LMP1 expression, phosphorylated and total levels of Rb and CDK2, and p21/Waf1.  Equal 
loading was confirmed with the actin blot. 
 
LMP1 variants regulate cell-cycle markers.  The ability to induce cell-cycle 
progression is a key step in oncogenesis.  Recent studies indicate that LMP1, through 
CTAR1, increases the levels of Id1 and Id3 as well as the pro-cellular growth markers 
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ppRb and CDK2 while reducing levels of the cdki p27/Kip1 (14, 27).  To determine 
whether the LMP1 variants could equally affect these cellular markers involved in cell 
cycle progression, Rat-1 cells were assayed by western blot analysis.  Confirming 
previous data with the B95.8 strain of LMP1, all variants induced higher levels of Id1 in 
Rat-1 cells compared to the pBabe control cells with reduced protein levels of the cdki 
p27/Kip1 (Fig. 6A). 
Densitometry on LMP1 expression as well as protein levels of p27 and Id1 from 
Figure 6A was performed (Fig. 6B).  The LMP1 bands for each variant that were used for 
densitometry analysis are delineated by an asterisk to their left.  LMP1 expression as 
detected by anti-HA was normalized to the B95.8 variant whereas levels of p27 and Id1 
were normalized to vector control (pBabe).  Expression levels of the LMP1 variants 
ranged from 289% to 106% compared to the B95.8 variant (white bars).  Protein levels of 
Id1 in cells expressing the LMP1 variants ranged from 143% to 250% compared to vector 
control (striped bars) whereas protein levels of p27 ranged from 24% to 59% compared to 
vector control (black bars).  Expression levels of the LMP1 variants did not directly 
correlate with more Id1 levels or less p27 levels.  These data suggest that LMP1 can only 
induce or repress Id1 and p27 to a certain level and that overexpression of LMP1 does not 
necessarily lead to an increase or decrease of these cellular markers. 
To determine the effects of LMP1 on cell cycle markers in normal epithelial cells, 
ppRb and CDK2 phosphorylation as well as total Rb levels were assessed in HFK cells 
expressing the LMP1 variants.  Similarly to Rat1 cells, higher levels of ppRb and total Rb 
and phosphorylated CDK2 were detected (Fig. 6C).  In contrast to the effects on p27, the 
cdki p21/WAF1 levels were unchanged suggesting specific effects of LMP1 on p27.  
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However, all LMP1 variants induced phosphorylation of Rb and CDK2 as well as an 
induction in overall Rb protein levels.  These data reveal that all LMP1 variants regulate 
a variety of cell cycle markers similarly to the well-characterized B95.8 LMP1 strain. 
LMP1 Variants induce homotypic adhesion of BJAB cells.  It has been 
established that expression of LMP1 in BJAB cells results in increased homotypic 
adhesion possibly due to increased LFA-1 or ICAM-1 levels (16, 33, 59).  BJAB stable 
cell lines expressing the LMP1 variants were established as mentioned previously and 
were observed for homotypic adhesion (Fig. 7A).  Similarly to that previously observed 
with the B95.8 strain (59), all LMP1 variants induced homotypic adhesion.  Although 
there was a small variation in the size and number of the cell clumps, overall there 
appeared to be no significant difference between the variants in their ability to induce 
homotypic adhesion. 
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Figure 7.  Homotypic adhesion of BJAB cells is induced by LMP1 variants.  (A) Equal 
number of BJAB cells stably expressing pBabe or the LMP1 variants were seeded and 
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observed for homotypic adhesion every 24 hours by phase contrast microscopy.  
Representative fields at 3 days post-seeding are shown.  (B) LMP1 variants activate Akt 
in BJAB cells.  BJAB cells stable expressing pBabe or the LMP1 variants were assayed 
for LMP1 expression and phosphorylated and total levels of Akt.  Equal loading was 
confirmed with an Actin blot. 
 
LMP1 expression in the BJAB cells was confirmed by western blot analysis.  All 
of the BJAB cell lines expressed detectable levels of LMP1 by CS1-4 (Fig. 7B), and the 
Alaskan strain by a pool of Rat monoclonal antibodies for LMP1 (data not shown).  All 
of the LMP1-expressing BJAB cells had higher levels of phosphorylated Akt indicating 
that activation of Akt by LMP1 occurs in both epithelial and lymphoid cells.  These data 
demonstrate that the LMP1 variants are capable of inducing phenotypic changes not only 
in epithelial cells, but also lymphocytes. 
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Figure 8.  Differential binding of HOS by LMP1 variants.  (A) Sequence alignment of 
the LMP1 variants from amino acids 207-370 of LMP1-B95.8 showing residues 
important for HOS-LMP1 binding, including the Destruction Box, a serine residue at 
amino acid 350, and a serine residue at amino acid 366.  The 10 amino acid deletion 
found in the China 1 and Med+ variants is represented by del.  Asterisks indicate amino 
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acids important for HOS-LMP1 binding.  B95.8 contains all residues required for HOS-
LMP1 binding.  (B) 293T cells co-transfected with pcDNA3 (vector control), the LMP1 
variants and HOS, or HOS alone were harvested 48 hours post transfection and analyzed 
for HOS-LMP1 binding through co-IP.  HOS was immunoprecipitated with anti-HA-
conjugated beads and western blot analysis for LMP1 was carried out with anti-c-myc.  
Western blot analysis of total protein (Total Load) confirmed expression of the LMP1 
variants, HOS, IκBα, β-catenin, and actin to confirm equal loading. 
 
Abrogated HOS binding enhances LMP1 NFκB activity.  The E3 ubiquitin 
ligase component HOS, a member of the β-TrCP/Fbw1 subfamily of F box proteins 
which targets β-catenin and IκBα, has been shown to bind to the B95.8 strain of LMP1 
but not the CAO strain.  This binding requires a destruction box motif close to CTAR1 
and two serines at amino acids 350 and 366 (53).  There are multiple changes in these 
required motifs in the LMP1 variants.  The Alaskan, China 1, China 2, and NC variants 
of LMP1 have a G212S mutation in the destruction box, China 1 and Med+ have a 10 
amino acid deletion that eliminates serine 350, and all the variants but B95.8 have a 
mutation that changes the serine at position 366 to threonine (Fig. 8A) (10). 
The ability of HOS to bind to the LMP1 variants was tested using transfection of 
293T cells and coimmunoprecipitations (co-IP) of HA-tagged HOS and myc-tagged 
LMP1 (Fig. 8B).  Immunoblotting with HA and myc revealed that HOS and the LMP1 
variants were efficiently expressed.  Immunoprecipitation with HA and blotting with myc 
indicated that the Alaskan, China 1, and Med+ variants of LMP1 bound HOS weakly 
compared to the B95.8, China 2, Med- and NC variants.  The low binding ability of 
China 1 to HOS is similar to that observed previously for the CAO strain.  The strong 
binding of Med-, which contains S350, compared to Med+ which is deleted for S350 
indicates that this is an important element in binding HOS.  The conservative change 
S366T in Alaskan, China 1, China 2, Med- and NC did not correlate with HOS binding as 
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Alaskan bound HOS very poorly in comparison to Med- and NC which bound strongly.  
These differences in binding suggest that multiple factors contribute to the HOS-LMP1 
interaction. 
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Figure 9.  All LMP1 variants activate NFκB.  293T cells were triple-transfected with 
pcDNA3 (vector control) or the LMP1 variants, pRL-SV40, and pGL3-Basic (vector 
control) or pGL-3κB (NFκB reporter).  48 hours post transfection cells were harvested 
and relative luciferase activity was assessed by the firefly luciferase activity of the NFκB 
reporter relative to the control Renilla luciferase activity (pRL-SV40).  The Tukey-
Krammer test was used to calculate p values.  All LMP1 variants had a p value of less 
than 0.001 compare to pcDNA3. 
 
To determine the effects of this binding on HOS targets, the levels of β-catenin 
and IκBα were determined.  The level of β-catenin were unchanged corroborating 
previous data that the LMP1-HOS interaction does not affect β-catenin levels (53).  The 
total levels of IκBα did not fully correlate with the levels of HOS-LMP1 binding.  China 
1, which bound HOS very poorly had the least amount of IκBα, confirming an earlier 
report (53) and most LMP1 variants had lower IκBα levels than the vector control.  
Interestingly, the B95.8-LMP1 which bound HOS well had more IκBα than the other 
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variants including pcDNA3 vector control. This is in contrast to the Med- and NC 
variants which also bound HOS very well but had lower levels of IκBα.  IκBα levels can 
be affected by multiple factors in addition to HOS binding including transcriptional 
regulation by NFκB and the activity of the IKK kinases.  Thus the absolute level of IκBα 
may not be reflective of its activity. 
To determine the ability of the LMP1 variants to induce NFκB activation, dual 
luciferase reporter assays were performed with the LMP1 variants in 293T cells (Fig. 9).  
Interestingly, activation of NFκB correlated with the ability of HOS to bind LMP1.  The 
Alaskan, China 1, and Med+ variants which bound HOS poorly induced higher NFκB 
reporter activity than the B95.8, China 2, Med-, and NC variants which bound HOS well 
and induced nearly equivalent NFκB activity.  The differences in reporter activity 
between all the LMP1 variants and pcDNA3 had a p value of less than 0.001 using the 
Tukey-Krammer Multiple Comparisons Test, thus indicating that they are statistically 
significant.  Furthermore, the increased reporter activity observed between the Alaskan, 
China 1, and Med+ variants compared to the B95.8 variant also had a p value of less than 
0.001.  Transfected HOS without LMP1 induced 2.4 fold more NFκB reporter activity 
suggesting that HOS can marginally induce NFκB reporter activity compared to LMP1.  
In addition, protein levels of the NFκB subunits p65/RelA and p50 were higher in the 
nuclear fractions of the LMP1 variants compared to pcDNA3 and correlated with the 
enhanced NFκB reporter activity (data not shown).  These data indicate that all of the 
LMP1 variants can activate NFκB signaling but those variants that do not bind HOS have 
enhanced NFκB activation. 
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DISCUSSION 
The data presented in this study indicate that all LMP1 variants transform Rat-1 
fibroblasts at an equal efficiency and activate the PI3K-Akt signaling pathway which is 
required for Rat-1 fibroblast transformation.  These data demonstrate that the signature 
amino acid changes in the LMP1 variants do not hinder or enhance their transforming 
potential in vitro.  The ability of all the LMP1 variants to activate the PI3K-Akt signaling 
was not unexpected as the ability for LMP1 to transform Rat-1 fibroblasts and activate 
PI3K-Akt signaling has been mapped to CTAR1 (7, 32), which is highly conserved 
amongst all the variants (10, 35).  The activation of the PI3K-Akt signaling pathway in 
BJAB cells also reveals that activation of this pathway is not restricted to epithelial cells 
but also occurs in B-lymphocytes.  Interestingly, activation of Akt had differential effects 
on known Akt targets as the phosphorylation and inactivation of GSK3β was 
significantly affected compared to the unchanged levels of phosphorylated mTOR.  The 
subcellular localization of activated Akt and/or availability of Akt targets likely 
contributes to these variable effects on regulation.  The association of LMP1 with lipid 
rafts (19) may target activation of Akt by limiting LMP1 to specific regions in the cell. 
PTEN is a tumor suppressor gene with mutation frequencies in human cancer 
approached that of p53 (5).  PTEN, a phosphatase, regulates PI3K signaling by reversing 
the PI3K-driven phosphorylation of phosphoinositides that are necessary for the 
downstream activation of Akt.  The LMP1 variants, including the B95.8 strain, did not 
affect the phosphorylation levels of PTEN and LMP1-expressing cells had slightly 
increased levels of PTEN.  These findings suggest that while LMP1 induces increased 
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PI3K-Akt signaling, it does not regulate this pathway through inhibiting the activity of 
PTEN. 
Cadherin molecules are a group of calcium-dependent transmembrane proteins 
that aid in cell-cell adhesion (18).  LMP1 has been shown to downregulate E-cadherin 
levels in NPC cell lines through activation of DNA methyltransferases (56).  Similarly to 
that observed with LMP1-B95.8, all LMP1 variants downregulated E-cadherin protein 
levels in Rat-1 cells.  These findings are congruent with the increased motility observed 
with the LMP1 variants. 
The Wnt/β-catenin signaling pathway is regulated by GSK3β which can 
phosphorylate β-catenin and induces β-catenin ubiquitination and proteasome-mediated 
degradation (37).  Inactivation of GSK3β through phosphorylation by Akt can lead to the 
accumulation of β-catenin in the cytoplasm followed by nuclear translocation where it 
interacts with TCF/LEF transcription factors to drive transcription of several genes (54).  
The EBV protein LMP2A also activates the PI3K-Akt pathway and induces GSK3β 
phosphorylation and β-catenin accumulation in the nucleus (38).  The data in this study 
reveals that LMP1 expression activated Akt and induced phosphorylation of GSK3β but 
did not affect nuclear β-catenin protein levels (data not shown and (13)).  This indicates 
that LMP1 does not affect β-catenin levels in epithelial cells in contrast to LMP2, which 
promotes β-catenin accumulation and nuclear translocation (38). 
The regulation of the cell cycle is an important step in oncogenesis and LMP1, 
through CTAR1, affects expression of several proteins that regulate G1/S progression, 
including Rb, CDK2, Id1 and Id3, and the cdki p27Kip1 (14).  All of the LMP1 variants 
had similar effects on the expression of these critical proteins, further suggesting that the 
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signature amino acid changes do not enhance or detract from the ability to deregulate the 
cell cycle.  Interestingly, the regulation of the cdki proteins by LMP1 appears to be 
limited to p27 as p21 levels were not changed in HFK cells.  Also, hyperphosphorylated 
and total protein levels of Rb were increased in LMP1-expressing HFK cells.  Although 
hyperphosphorylated Rb can be targeted for proteasomal degradation (30), LMP1-
expressing cells also had increased total levels of Rb.  Higher total and 
hyperphosphorylated levels of Rb were also observed in BL41 cells expressing the B95.8 
strain of LMP1 (1), suggesting that LMP1 may either block Rb degradation or induce 
increased Rb expression while also inducing its hyperphosphorylation. 
It has been documented that LMP1 activates the NFκB signaling pathway through 
both CTAR1 and CTAR2 (2, 8, 21, 34, 36, 55).  It has also been demonstrated that the 
CAO strain, most similar to China 1, and Med+ activate NFκB signaling to a larger 
extent (4, 34).  Subsequently, the increased NFκB activity observed with CAO was 
reported to be due to its lack of HOS binding, an E3 ubiquitin ligase component that 
regulates IκBα turnover (47, 53, 60).  The data presented here confirms that link as 
increased NFκB reporter activity was observed with the Alaskan, China 1, and Med+ 
variants compared to B95.8 and the other variants that bound HOS.  However, the 
proposed motifs required for HOS binding did not correctly predict HOS-LMP1 binding 
indicating that HOS-LMP1 binding is more complex than previously described.  
Furthermore, IκBα protein levels did not correlate with HOS-LMP1 binding, suggesting 
that IκBα turnover is regulated by other factors other than HOS.  
Enhanced NFκB signaling of the LMP1 strain Med+ was previously mapped to 
the transmembrane domains (34).  Other data indicate the 1st and 6th transmembrane 
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domains of LMP1 are important for proper signaling.  Six leucine repeats have been 
identified that may confer a specific structure when LMP1 self-assembles in the cellular 
membrane (23) and a FWLY motif in the 1st transmembrane domain that possibly 
mediates interactions between LMP1 and other molecules in lipid rafts (61).  The 1st 
transmembrane domain of the Alaskan and China 2 variants contain two isoleucine 
mutations in the 6-leucine repeat although the isoleucine substitutions do not disrupt 
LMP1 signaling with the B95.8 strain (23).  In addition, the FWLY motif is unchanged in 
all the variants.  These data suggest that multiple properties of LMP1 contribute to 
activation of NFκB signaling including HOS binding and self-aggregation which may be 
affected by the leucine repeats and the FWLY motif. 
However, it should be noted that all LMP1 variants induce robust NFκB reporter 
activity.  Activation of NFκB is required for continued growth of EBV transformed 
lymphocytes but is not required for rodent fibroblast transformation.  This study reveals 
that all of the LMP1 variants activate both NFκB and PI-3K/Akt signaling and have 
equivalent effects on cell growth and transformation.  It has previously been shown that 
the sequence changes that distinguish the LMP1 variants are preferentially located within 
known and predicted Class I HLA epitopes (11).  The similar biologic and biochemical 
properties of the variants described in this study may suggest that these variants arose and 
are maintained through immune selection. 
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CHAPTER FOUR 
 
 
 
 
 
UNIQUE SIGNALING PROPERTIES OF CTAR1 IN LMP1-MEDIATED 
TRANSFORMATION 
 
Bernardo A. Mainou and Nancy Raab-Traub
ABSTRACT 
 The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is the EBV 
oncogene as it is necessary for EBV-mediated transformation of B-lymphocytes and itself 
transforms rodent fibroblasts.  LMP1 activates the NFκB, PI3K-Akt, MAPK and JNK 
signaling pathways through its two signaling domains carboxyl-terminal activating regions 1 
and 2 (CTAR1 and CTAR2).  CTAR1 and CTAR2 induce signal transduction pathways 
through their direct, CTAR1, or indirect, CTAR2, recruitment of TNFR-associated factors 
(TRAFs).  CTAR1 has been demonstrated to be necessary for LMP1-mediated 
transformation as well as activation of PI3K signaling and induction of cell cycle markers 
associated with G1/S transition.  In this study, dominant negative forms of TRAF2 and 
TRAF3 inhibited, but did not fully block, LMP1-mediated transformation.  Activation of 
PI3K-Akt signaling as well as the deregulation of cell-cycle markers was mapped to the 
TRAF-binding domain within CTAR1 and to the residues between CTAR1 and CTAR2.  
Activation of the MEK1/2-ERK1/2 signaling pathway through the TRAF-binding site was 
necessary for LMP1-induced transformation of Rat-1 fibroblasts.  These findings identify a 
new signaling pathway that is uniquely activated by the TRAF-binding domain of LMP1. 
 
INTRODUCTION 
 Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that is associated with a variety 
of malignancies including nasopharyngeal-carcinoma (NPC), Hodgkin lymphoma, post-
transplant lymphoma, and others (28, 41, 53, 54).  The EBV-encoded latent membrane 
protein 1 (LMP1) is considered the EBV oncogene as it is essential for EBV-mediated B-
lymphocyte and itself can transform rodent fibroblasts (2, 27, 49).  LMP1 is frequently 
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expressed in EBV malignancies, such as the aforementioned NPC and Hodgkin lymphoma 
(18, 53). 
 LMP1 consists of 386 amino acids that form a short 23 amino-terminal cytoplasmic 
end, six hydrophobic transmembrane domains, and a long carboxyl-terminal tail that contains 
the two main signaling domains, carboxyl-terminal activating regions 1 and 2 (CTAR1 and 
CTAR2).  LMP1 self-associates in the plasma membrane.  Not requiring a ligand, LMP1 acts 
as a constitutively active tumor necrosis factor receptor (TNFR) by mediating signaling 
through the recruitment of TNFR-associated factors (TRAFs) by CTAR1 or through 
recruitment of adapter molecules such as TNFR-associated death domain (TRADD) or the 
Receptor Interacting Protein 1 (RIP1) by CTAR2 (23, 25, 38).  CTAR1 recruits TRAF1/2 or 
TRAF3/5 heterodimers through a consensus TRAF binding domain (PQQAT) whereas 
CTAR2 recruits TRAFs 2 and 6 through adapter molecules (28). 
LMP1 activates various signaling pathways including NFkB, mitogen-activated 
protein kinase (MAPK), c-Jun N-terminal kinase, and phosphatidylinositol 3-kinase (PI3K)-
Akt pathways (9, 16, 25, 33, 37, 40, 42, 47).  LMP1 also induces the deregulation of various 
cellular markers associated with G1/S cell-cycle transition, including the upregulation of the 
inhibitor of differentiation (Id) 1 and 3,  downregulation of cyclin-dependent kinase inhibitor 
(cdki) p27Kip1 and p16INK4a, upregulation of  cyclin dependent kinase 2 (CDK2), and 
upregulation retinoblastoma (Rb) (17, 29, 39). 
 Although both CTAR1 and CTAR2 recruit TRAFs, they yield different effects on the 
signal transduction pathways they activate.  CTAR1, but not CTAR2, is necessary for rodent 
fibroblast transformation and EBV-mediated B-lymphocyte transformation (25, 33).  
Although CTAR2 induces the bulk of NFκB signaling, CTAR1 induces a more complex 
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signal, inducing both canonical and non-canonical forms of NFκB including p50/p50 and 
p50/p52 dimers (14, 26, 35, 48).  While CTAR2 activates the JNK signaling cascade, 
CTAR1 activates PI3K-Akt signaling, including the Akt target glycogen synthase kinase β 
(GSK3β) and induces unique effects in cellular gene expression including the induction of 
epithelial growth factor receptor (EGFR), TRAF1, and Id1 and Id3 while repressing p27 (10, 
11, 13, 17, 33, 36).  The activation of PI3K-Akt, but not NFκB, is required for Rat-1 
fibroblast transformation (33). 
 The presence or absence of a specific TRAF can determine the outcome of the signal 
being transduced by LMP1.  Although CTAR2, but not CTAR1, activates JNK signaling in 
epithelial cells, overexpression of TRAF1 allows CTAR1 to activate JNK signaling (15).  In 
TRAF2 and TRAF5 knockout mouse embryo fibroblasts (MEF) LMP1 mediated NFκB 
activation is similar to wild-type MEFs and this activation is highly dependent on TRAF6 
(32).  In contrast, in mouse lymphoma cells, NFκB and IgM secretion are almost completely 
TRAF3 dependent (51, 52). 
 In this study, the role of the TRAF-binding domain, TRAF2, and TRAF3 in rodent 
fibroblast transformation and signal transduction was evaluated.  Blockade of TRAF2 or 
TRAF3 signaling with dominant negative TRAFs (dnTRAF) impaired, but did not block, 
LMP1-induced transformation of Rat-1 cells.  LMP1 mutants in the carboxyl-terminal tail 
and the TRAF-binding domain indicate that CTAR1 mediates the majority of PI3K-Akt 
signaling, deregulation of cellular markers associated with G1/S transition and induces a 
decrease in the protein levels of the desmosome-associated protein plakoglobin.  The 
activation of extracellular signal regulated kinase (ERK1/2) was uniquely activated by 
CTAR1 and this activation is necessary for LMP1-mediated transformation of rodent 
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fibroblasts.  These data identify a signaling pathway that is uniquely activated by CTAR1 
and is necessary for LMP1-mediated transformation. 
  
MATERIALS AND METHODS 
Plasmids.  LMP1 and LMP1 mutants were cloned into the pBabe-puromycin (pBabe) 
vector with a hemagglutinin (HA) tag at the amino-terminus.  LMP1-A5 (204-208AAAAA), 
LMP1∆204-208, LMP1-204/6AA, and LMP1-208A were subcloned from plasmids described 
in (35) into pBabe with the same primers used to clone full-length LMP1 in (17).  Truncation 
mutants with unaltered CTAR1 utilized the full-length LMP1 construct and truncation 
mutants with a mutated CTAR1 (A5) utilized the LMP1-A5 construct.  PCR amplification of 
the LMP1 mutants used the same 5’ primer (LMP1-HA5’ used to clone full-length LMP1) 
but different 3’ primers.  1-187 3’ primer 3TMSTOP 
(ATCACGAGGAATTCCTATTAATGGTAATACATCCAGATTAAAATCGCC).  1-195 
with the 3’ primer 3TM195 
(ATCACGAGGAATTCCTATTAGTGTTCATCACTGTGTCGTTGTC).  1-203 with the 3’ 
primer 3TM203 (ATCACGAGGAATTCCTATTAGTGCGGGAGGGAGTCATC).  1-208 
with the 3’ primer TM-208 
(ATCACGAGGAATTCCTATTAGGTAGCTTGTTGAGGGTGCG).  1-208-A5  with the 3’ 
primer TM-2085A (ATCACGAGGAATTCCTATTAGGCAGCTGCTGCAGCGTG).  1-220 
and 1-220 A5 with the 3’ primer 3TM220 
(ATCACGAGGAATTCCTATTAGTTGGAGTTAGAGTCAGATTCATGG).  LMP1-
378Stop and A5-378Stop with the 3’ primer 378STOP 
(ATCACGAGGAATTCCTATTAGCCGTGGGGGTCGTCATC).  LMP1-Y384G and A5-
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Y384G with the 3’ primer Y384G 
(ATCACGAGGAATTCCTATTATTAGTCATAGCCGCTTAGCTGAACTGG).  PCR 
amplification was followed by restriction enzyme digestion and insertion into the BamHI and 
EcoRI sites of pBabe-M3 (with puromycin or hygromycin cassette). 
An expression cassette encoding three tandem myc-epitope tags was moved from 
M3-LMP1 (17) to pBabe-puro for retroviral expression of myc-tagged proteins.  The myc-tag 
was amplified with M3EBH5’ 
(CGCCGGATCCAGATCTAAGCTTGCCGCTCGAGCCACCATGGAACAAAAG) and 
M3Bam3’ (CGTGTTCCATATGGATCCGAG), digested with Bgl II and BamH I, and 
cloned into the BamH I site of pBABEpuro.  Cloning in frame with the myc-tag results in 
triple-myc-tagged proteins. 
The dominant negative TRAF6 (dnTRAF6) construct was a gift from Ilona Jaspers 
(7).  Dominant negative TRAF2 (dnTRAF2) and dominant negative TRAF3 (dnTRAF3) 
were subcloned in frame into pBabe-M3 (containing a triple myc tag) from plasmids 
described in (37).  dnTRAF2 was PCR amplified with the 5’ primer TRF2DN5’ 
(CGACGGATCCATAGGGAGGTGGAGAGCCTGCCG) and the 3’ primer TRF2DN3’ 
(ATCACGAGGTCGACTTAGAGCCCTGTCAGGTCCACAATGG).  dnTRAF3 was PCR 
amplified with the 5’ primer TRF3DN5’ 
(CGACGGATCCTAGAGGAAGCAGACAGCATGAAGAGCAG) and the 3’ primer 
TRF3DN3’ (ATCACGAGGTCGACTCAGGGATCGGGCAGATCCGAAG).  PCR 
amplification was followed by restriction enzyme digestion and insertion into the BamHI and 
SalI sites of pBabe-M3 (puromycin and hygromycin).  1-231 was described previously (17). 
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LMP1 was cloned into retroviral packaging vector pHSCG (kindly provided by 
Lishan Su, UNC-CH, (8)) co-expressing GFP under the control of the CMV promoter.  HA-
tagged LMP1 was amplified using HA-EcoRI 
(GCCGAATTCATGGCTTACCCATACGATGTTCCAG) and LMP1 SalI 
(GCGGTCCAGAATGTGGCTTTTCAGCCTAGAC) primers, digested with EcoR I and Sal 
I, and ligated into the EcoR I and Xho I sites of pHSCG by compatible ends. 
Retrovirus production and transduction.  Retrovirus production was prepared as 
described previously (17).  Briefly, subconfluent HEK-293T (293T) cells were triple 
transfected with 5µg of pBabe or pHSCG or each of the pBabe-HA-tagged LMP1 constructs 
or pHSCG-LMP1, 5µg of pVSVG, and 5µg of pGag/Pol using Fugene 6 (Roche) transfection 
reagent according to the manufacturers directions.  Following overnight incubation at 37ºC 
the media were replaced with fresh media (DMEM (GIBCO) with 10% fetal bovine serum 
(FBS; Sigma) and antibiotic/antimycotic (GIBCO)) and cells were incubated at 33ºC 
overnight.  Cell supernatant containing the retrovirus was clarified by centrifugation at 1,000 
x g for 5 min.  Rat-1 cells were then transduced with the clarified supernatant and 4 µg/ml 
polybrene overnight. 
Cell culture and stable cell lines.  Rat-1 fibroblasts and 293T cells were maintained 
in DMEM supplemented with 10% FBS (Sigma) and antibiotic/antimycotic (GIBCO).  Rat-1 
cells were prepared fresh and maintained for no more than 5 passages for each experiment.  
Stable cell lines with pBabe, the LMP1 constructs, or the dnTRAFs were established by 
transduction with recombinant retrovirus followed by selection with 5µg/ml of puromycin 
(Sigma).  Alternatively dnTRAF stable cells were kept under hygromycin (Cellgro) at a 
concentration of 200µg/ml. 
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 Focus formation and soft agars.  Subconfluent Rat-1 cells were transduced with 
recombinant retrovirus in six-well plates overnight.  Cells were then maintained by changing 
the media every other day for 10-14 days.  To assay for focus formation in the presence of 
U0126 (Calbiochem), stable cell lines were established as described previously and seeded in 
duplicate six well plates.  Upon reaching confluence and every other day thereafter for 7-10 
days, fresh media containing 10µM U0126 or vehicle control (dimethyl sulfoxide; DMSO 
from Sigma) was added to the cells.  Cells were then stained with 1% crystal violet in 50% 
ethanol and imaged with a stereo microscope.   
Soft agar assays were performed as described previously (33, 45).  Briefly, Bacto agar 
medium (5% Bacto agar in DMEM with 10% FBS and antibiotic/antimycotic to a 0.5% final 
concentration) was poured into a 12-well plate and allowed to solidify.  1.0 x 105 to 2.0 x 105 
cells/well were resuspended in Bacto agar medium, over-laid on the initial layer of solidified 
Bacto agar medium and allowed to solidify.  Medium was added on top of the solidified 
Bacto agar medium and changed every 2-3 days for 14-21 days.  For the dnTRAF soft agars, 
medium was supplemented with 5µg/ml of puromycin to maintain stable expression of the 
dnTRAFs.  Cells were imaged with phase-contrast microscopy and fluorescence microscopy 
to verify GFP expression. 
 Cell harvesting and western blotting.  Cell lines were grown to confluence and 
harvested as described previously (17).  Briefly, after being harvested, cells were washed 
with ice-cold PBS (GIBCO), centrifuged at 1,000 x g, and lysed with 
radioimmunoprecipitation assay buffer (RIPA; 20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM 
EDTA, 1% NP40, 0.1% sodium dodecyl sulfate (SDS), 0.1% deoxycholate, 0.5mM 
phenylmethylsulfonyl fluoride (PMSF), 1mM Na3VO4, and protease and phosphatase 
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inhibitor cocktails from Sigma).  Lysates were incubated on ice for 10 minutes, clarified by 
centrifugation, and protein concentration was determined using the Bio-Rad DC protein 
assay system.  Lysates were boiled in SDS-sample buffer for 5 minutes, 12.5 or 25.0 µg of 
protein was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to an Optitran membrane (Whatman) for western blot analysis, and efficient 
transfer was confirmed with Ponceau S staining (Fluka).  Primary antibodies used included 
HA probe (Covance), c-myc tag, β-actin, TRAF6, phospho-ERK1/2 (Y473), total ERK1/2, 
PARP (Santa Cruz), plakoglobin (Abcam), CDK2, Rb (BD Biosciences), total GSK3 
(Upstate Biotechnology), phospho-Rb (Oncogene, p27/KIP (Calbiochem and Cell Signaling), 
phospho-GSK3β (S9), phospho-CDK2 (T160), phospho-Akt (S473), total Akt (Cell 
Signaling).  Densitometry analysis was done with Image J software. 
 
RESULTS 
CTAR1 is necessary for rodent fibroblast transformation.  LMP1 is considered 
the EBV oncogene for its ability to block contact-inhibited growth and induce anchorage-
independent growth in Rat-1 fibroblasts (17, 33, 49).  CTAR1, but not CTAR2, is required 
for rodent fibroblast transformation (33).  To assess the role of the TRAF-binding domain in 
rodent fibroblast transformation two TRAF-binding domain mutants were developed.  
LMP1-A5 has the TRAF-binding domain mutated from PQQAT to AAAAA and 
LMP1∆204-208 has a deletion of the TRAF-binding domain encompassing amino acids 204-
208.  To determine whether these constructs were able to block contact-inhibited growth Rat-
1 fibroblasts were transduced with pBabe (vector), LMP1, 1-231 (LMP1 deleted for amino 
acids 232-386), LMP1-A5, and LMP1∆204-208.  Ten days post transduction cells were 
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analyzed for block of contact-inhibited growth as presented by focus formation (Fig. 1).  
Whereas LMP1 and 1-231, both of which contain CTAR1, induced focus formation, pBabe 
and the two TRAF-binding domain mutants, LMP1-A5 and LMP1∆204-208 did not.  
Western blot analysis on parallel transduced cells confirmed expression of all four constructs 
indicating that the failure to block contact-inhibited growth was not due to failed transduction 
or expression (data not shown).  These data reveal that the TRAF-binding domain, amino 
acids 204-208, is necessary for rodent fibroblast transformation. 
pBabe LMP1 1-231
LMP1-A5 LMP1∆204-208
 
FIG 1.  TRAF-binding domain is necessary for LMP1-mediated block of contact-inhibited 
growth.  Rat-1 fibroblasts were transduced with pBabe, LMP1, 1-231, LMP1-A5 or 
LMP1∆204-208, maintained for 10 days, stained with crystal violet and observed for focus 
formation. 
 
 LMP1-mediated transformation is impaired by dnTRAF2 and dnTRAF3.  The 
interaction of CTAR1 with several TRAFs, including TRAFs 1, 2, 3, and 5, mediate the 
activation of signal transduction pathways such as NFκB and induction of key pro-growth 
cellular molecules like the EGFR (4, 11, 12, 35, 37, 51).  To determine if TRAF2 and/or 
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TRAF3 mediate the ability of LMP1 to block contact-inhibited growth stable Rat-1 cell lines 
expressing pBabe-M3, dominant negative TRAF2 (dnTRAF2) or dominant negative TRAF3 
(dnTRAF3) were established followed by transduction with three serial dilutions of either 
pBabe or LMP1. Duplicate plates were harvested and expression of the dnTRAFs and LMP1 
was confirmed by western blot analysis (data not shown).  DnTRAFs contain the TRAF-
binding domain but have been deleted of their RING and zinc-finger domains thus allowing 
interaction with their target molecule while impairing their ability to induce signaling upon 
their recruitment.  Fourteen days post-transduction cells were observed for focus formation 
(Fig. 2).    Transduction of the pBabe-M3 (vector) stables with pBabe (pBabe-M3-pBabe-
puro), or the stable cells expressing only dnTRAF2 or dnTRAF3 did not show signs of focus 
formation.  In contrast, transduction of the pBabe-M3, dnTRAF2, or dnTRAF3 stable cells 
with LMP1 induced focus formation.  Furthermore, Rat-1 cells stably expressing dnTRAF6 
transduced with LMP1 formed foci to similar levels than the vector control cells, indicating 
that TRAF6 is not involved in mediating LMP1 signals involved in transformation (data not 
shown). 
Although dnTRAF2 or dnTRAF3 did not completely ablate focus formation they 
markedly reduced the number of foci.  Quantitative analysis of the foci showed that 
dnTRAF2 and dnTRAF3 repress focus formation by around 2.5 fold (data not shown).  
Furthermore, anchorage-independent growth was also impaired, but not fully blocked, by 
either dnTRAF2 or dnTRAF3 (data not shown).  These data suggest that TRAF2 and 
TRAF3, but not TRAF6, contribute in LMP1-mediated transformation but are not fully 
required for the transformation process.  The inability for dnTRAF2 and dnTRAF3 to fully 
block LMP1-mediated transformation suggests that some redundancy is associated with 
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LMP1-TRAF signaling.  Indeed, in TRAF2 and TRAF5 knockout MEFs, LMP1 can still 
mediate nuclear translocation of the NFκB subunit p65 (31). 
pBabeM3-LMP1 10-2
dnTRAF3pBabeM3-pBabepuro dnTRAF2
pBabeM3-LMP1 10-1
dnTRAF3-LMP1 10-2dnTRAF3-LMP1 10-1dnTRAF2-LMP1 10-2dnTRAF2-LMP1 10-1
pBabeM3-LMP1 10-3
 
FIG. 2.  LMP1-mediated transformation of Rat-1 fibroblasts is inhibited by dnTRAF2 and 
dnTRAF3.  Rat-1 fibroblasts stably expressing pBabe-M3, dnTRAF2, or dnTRAF3 were 
transduced with pBabe or LMP1 with three serial dilutions, maintained for 14 days, stained 
with crystal violet and observed for focus formation. 
 
 Role of CTAR1 in LMP1 signal transduction.  To further evaluate the role of 
CTAR1 in the induction of several signal transduction pathways additional LMP1 mutants 
were constructed (Fig. 3).  The serial truncation LMP1 mutants encompass from the start of 
the carboxyl-terminal tail at amino acid 188 to amino acid 231.  Two more full-length LMP1 
mutants of CTAR1, LMP1-204/6AA (two alanine substitutions at amino acids 204 and 206) 
and LMP1-208A (alanine substitution at amino acid 208), were subcloned to evaluate the 
role of CTAR1.  Finally, a CTAR2 deletion mutant (LMP1-378Stop) and a point mutant that 
has been described to abrogate most CTAR2 activity (LMP1-Y384G) were constructed with 
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a functional CTAR1 and a mutant CTAR1 (A5-378Stop and A5-Y384G) (3, 19).  All LMP1 
constructs were hemagglutinin (HA)-tagged on the amino-terminus. 
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FIG. 3.  Graphical representation of LMP1 mutants.  All constructs are amino-terminal HA 
tagged.  CTAR1 and CTAR2 are represented by a circle with number “1” or “2” respectively.  
Substitutions to CTAR1 or CTAR2 are underlined.  Bottom row delineates truncation 
mutants. 
 
 Rat-1 fibroblasts stably expressing pBabe, LMP1, LMP1∆204-208, 1-187, 1-195, 1-
203, 1-220, and 1-231 were assayed for their ability to modulate three aspects of 
transformation that have been linked to LMP1; PI3K-Akt signaling, cell-cycle deregulation, 
and cellular adhesion (Fig. 4A).  Expression of LMP1 was confirmed using antibodies 
against the amino-terminal HA-tag.  The variation in the levels of LMP1 expression are due 
to ubiquitination and proteasomal degradation being mediated by CTAR1-TRAF binding 
(43).  As reported previously, full-length LMP1 induced activation of the PI3K-Akt signaling 
pathway as represented by phosphorylation and inactivation of the Akt-target GSK3β.  
Furthermore, the LMP1 mutants 1-220 and 1-231, which are deleted for CTAR2, also 
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induced increased levels of phosphorylated GSK3β although 1-231 had the strongest 
induction.  Interestingly, deletion of the TRAF-binding domain in full-length LMP1 
(LMP1∆204-208) resulted in a 2 fold reduction of phosphorylated GSK3β compared to full-
length LMP1 (Fig. 4B). 
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FIG. 4.  CTAR1 induces activation of PI3K-Akt signaling and deregulates markers 
associated with cell-cycle progression.  (A) Rat-1 stable cells expressing pBabe, LMP1, or 
LMP1 mutants were assayed for expression with HA antibodies, phosphorylated-GSK3β 
(S9), total GSK3 (α and β forms), plakoglobin, CDK2 (hyperphosphorylated CDK2 is 
marked by the arrowhead), total Rb, and actin as a loading control by western blot analysis.  
(B)  Quantitative analysis of protein levels of pGSK3b (white bars), plakoglobin (black bars), 
and Rb (striped bars).  Values are in fold induction compared to pBabe. 
 
Increased levels of hyperphosphorylated CDK2 (top band; arrowhead) and increased 
levels of total Rb, cellular markers involved in G1/S cell-cycle progression, were observed in 
LMP1, LMP1∆204-208, 1-220, and 1-231.  Plakoglobin, a cellular protein associated with 
cell-cell adhesion, was also downregulated by LMP1, LMP1∆204-208, 1-220, and 1-231.  
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The ability of the non-transforming LMP1∆204-208 to modulate GSK3β, plakoglobin, 
CDK2 and Rb to similar levels as the transforming 1-220 is surprising.  Comparison of the 
truncation mutants, 1-187, 1-195, 1-203, 1-220, and 1-231, suggest that the TRAF-binding 
domain is required to modulate these cellular changes.  However, comparison of LMP1 and 
LMP1∆204-208 indicates that the TRAF-binding domain is only partially responsible for 
these cellular effects.  These data indicate that although CTAR1, or TRAF-binding domain, 
is the main effector in modulating these cellular pathways, there is another site within full-
length LMP1 that augments the ability of the TRAF-binding domain to affect these cellular 
changes. 
 
 Mutations in CTAR1 ameliorate LMP1 transforming potential.  Two residues 
within the TRAF-binding domain, the proline at amino acid 204 and the glutamine at 
position 206, that constitute CTAR1 have been found to play an important role in TRAF 
binding (35).  To further evaluate the role of the residues within CTAR1 in rodent fibroblast 
transformation, Rat-1 cells were transduced with pBabe, LMP1, LMP1-A5, 1-195, 1-203, 1-
208, 1-208-A5, 1-220, 1-220-A5, 1-231, LMP1-204/6AA, and LMP1-208A and assayed for 
the ability to block contact-inhibited growth (Fig. 5).  LMP1, 1-220, 1-231, LMP1-208A, and 
LMP1-204/6AA formed foci.  Although LMP1-204/6AA was not fully inhibited for focus-
formation, it was highly impaired in the ability to block-contact inhibited growth as 
represented by smaller foci.  LMP1-208A formed foci to similar levels than LMP1 indicating 
that the threonine residue at position 208 in the TRAF-binding site is not necessary for 
transformation.  Although 1-208 did not form foci even though the TRAF-binding site is 
intact, previous studies demonstrated that the aspartic acid residue at position 210 is 
necessary for proper TRAF3 binding, suggesting that 1-208 could be non-transforming due 
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to a TRAF-binding defect (50).  Furthermore, substitution of CTAR1 to all alanine residues 
(LMP1-A5 or 1-220-A5) or deletion of CTAR1 (1-195 or 1-203) inhibited transformation.  
These data indicate that the TRAF-binding site is required for transformation and that the 
residues between amino acids 208 and 220 are required for transformation. 
pBabe LMP1 LMP1-A5 1-195
1-203 1-208 1-208-A5 1-220
1-220-A5 1-231 LMP1-204/6AA LMP1-208A
 
FIG. 5.  Mutation of proline and glutamine residues in CTAR1 impair LMP1-induced 
transformation.  Rat-1 cells were transduced with pBabe, LMP1, or LMP1 mutants, 
maintained for 14 days, stained with crystal violet and observed for focus formation. 
 
  
Effects of mutation of TRAF-binding domain in LMP1 signaling.  To evaluate the 
role of CTAR1 and the amino acids surrounding CTAR1 in LMP1-mediated signal 
transduction, Rat-1 stable cells expressing LMP1 and several LMP1-mutants were 
established and their ability to induce various signal transduction pathways was assessed 
through western blot analysis (Fig. 6).  LMP1, 1-208, 1-220, 1-231, and LMP1-208A had a 
moderate increase of phospho-GSK3β (Fig. 6A).  Mutation (LMP1-A5) or deletion 
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(LMP1∆204-208) in full-length LMP1 resulted in a small decrease, 18% and 7% decrease 
respectively, in the levels of phospho-GSK3β.  Mutation of the TRAF-binding site in a 
truncated LMP1 (1-208 or 1-220) resulted in a large decrease, 3.9 and 2.6 fold respectively, 
in phospho-GSK3β (Fig. 6B). 
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FIG. 6.  Redundancy in LMP1-induced inactivation of GSK3β.  (A) Rat-1 stable cells 
expressing pBabe, LMP1, or LMP1 mutants were assayed for LMP1 expression with HA 
antibodies, phosphorylated GSKβ, total GSK3 (α and β subunits), actin as a loading control 
and total Rb.  (B) Quantitative analysis of phosphorylated GSKβ protein levels.  Values are 
represented as fold induction compared to pBabe and are normalized to total actin levels. 
 
Total Rb levels were significantly upregulated by LMP1, LMP1-A5, 1-220, 1-231, 
and LMP1-208A and slightly by 1-208.  Although LMP1∆204-208, LMP1-A5, and 1-208 are 
non-transforming they all had increased levels of phosphorylated GSK3β and total Rb.  Total 
Rb levels have been demonstrated to be increased concomitant with the hyperphosphorylated 
form in the presence of LMP1, but the role of increased Rb levels remains to be determined 
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(34).  Mutation of the TRAF-binding site in 1-208 or 1-220 inhibited the ability of LMP1 to 
modulate GSK3β and Rb.  In contrast, mutation of the TRAF-binding site in full-length 
LMP1, LMP1∆204-208 and LMP1-A5 marginally affected the modulation of GSK3β and 
Rb. 
 Rat-1 cells stably expressing LMP1 and several LMP1 mutants were also assayed for 
their ability to deregulate the cell cycle marker p27Kip1 as well as the cell adhesion protein 
plakoglobin (Fig. 7A).  LMP1, LMP1-A5, 1-208, 1-220, 1-231, LMP1-204/6AA and LMP1-
208A decreased the protein levels of p27 and plakoglobin.  Although 1-195, 1-203, 1-208-A5 
and 1-220-A5 had between 1.5-2.7 fold higher levels of p27 the relevance of this finding is 
still being evaluated (Fig. 7B). 
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FIG. 7.  Redundancy in LMP1-induced deregulation of p27 and plakoglobin levels.  (A) Rat-
1 cells stably expressing pBabe, LMP1 or LMP1 mutants were assayed for LMP1 expression 
with HA antibodies, p27, plakoglobin, or actin as a loading control by western blot analysis.  
(B) Quantitative analysis of p27 (black bars) and plakoglobin (white bars) protein levels.  
Values shown are fold induction in relationship to pBabe. 
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Mutation of the TRAF-binding site in 1-208 or 1-220 abrogated the LMP1-mediated 
downregulation of p27 and plakoglobin.  In contrast, mutation of the TRAF-binding site in 
full-length LMP1, LMP1-A5, did not affect the LMP1-induced downregulation of these 
proteins.  Furthermore, LMP1-204/6AA and LMP1-208A had similar levels of p27 and 
plakoglobin to LMP1 and LMP1-A5.  The modulation of these markers do not correlate with 
their ability to transform Rat-1 cells as LMP1-A5 and 1-208 are non-transforming but they 
can still modulate these cellular markers.  These data suggest that the TRAF-binding site is 
the main effector in the induction of PI3K-Akt signaling, as measured by GSK3β 
phosphorylation, the deregulation of cell-cycle markers Rb and p27, and the cell adhesion 
marker plakoglobin.  These data also suggest that a site between the TRAF-binding site and 
CTAR2 aids in the modulation of these cellular markers. 
 ERK1/2 activation is necessary for LMP1-mediated transformation.  LMP1 was 
previously demonstrated to induce activation of ERK1/2 in Rat-1 fibroblasts (6, 42).  To 
determine the role of CTAR1 in ERK1/2 activation Rat-1 stable cells expressing pBabe, 
LMP1, or various LMP1-constucts were assayed for ERK1/2 activation by western blot 
analysis (Fig. 8A).  LMP1, LMP1-204/6AA, LMP1-208A, LMP1-Y384G, LMP1-378Stop 
and 1-220 had increased levels of phosphorylated ERK1/2.  In contrast to that observed with 
phosphorylated GSK3b, Rb, p27, and plakoglobin, activation of ERK1/2 was observed only 
in cells expressing LMP1 or LMP1 constructs that were transforming.  LMP1-A5 and 1-208, 
which are non-transforming, had significantly reduced levels of phospho-ERK1/2 compared 
to LMP1 and 1-220, which are transforming.  Mutation or deletion of CTAR2 (LMP1-
Y384G, A5-Y384G, LMP1-378Stop, or A5-378Stop), whether in the presence or absence of 
a wild-type TRAF-binding site, did not affect the phosphorylation levels of ERK1/2.  These 
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data indicate that the CTAR1-mediated activation of ERK1/2 plays an important role in 
LMP1-mediated transformation of rodent fibroblasts as it is only detected in the presence of 
LMP1 constructs that transform Rat-1 cells. 
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FIG. 8.  CTAR1 is necessary for LMP1-induced activation of ERK1/2.  (A) pBabe, LMP1 or 
LMP1 mutants stably expressed in Rat-1 cells were assayed for LMP1 expression by HA 
antibodies, phosphorylated ERK1/2 (Y204), total ERK1/2, p27, or actin as a loading control 
by western blot analysis.  (B) Quantitative analysis of phosphorylated ERK1/2 protein levels.  
Values shown as fold induction over pBabe. 
 
Protein levels of p27 were lower than pBabe in LMP1, LMP1-A5, and LMP1-
204/6AA and marginally lower in LMP1-208A indicating that the LMP1 can downregulate 
p27 levels in the absence of the TRAF-binding site.  Deletion (LMP1-378Stop and A5-
378Stop) or mutation (LMP1-Y384G or A5-Y384G) of CTAR2 did not affect the 
downregulation of p27 indicating that CTAR2 is not involved in the regulation of p27.  In the 
context of a truncated LMP1 (1-230, 1-208 or 1-220) the TRAF-binding site is required for 
p27 downregulation as mutation of the site (1-208-A5 or 1-220-A5) abrogates the LMP1-
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induced downregulation.  Densitometry analysis was performed to quantitate the levels of 
phosphorylated-ERK1/2 (Fig. 8B).  These data indicate that ERK1/2 activation is mediated 
strictly by the TRAF-binding site, whereas p27 downregulation is induced by CTAR1 and 
another signaling motif that is not CTAR2. 
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FIG. 9.  ERK1/2 activation is necessary for LMP1-mediated block of contact-inhibited 
growth.  (A) Rat-1 cells stably expressing pBabe, LMP1, or LMP1 mutants were seeded to 
confluency, treated with vehicle control (DMSO) or U0126 for 7 days, stained with crystal 
violet, and observed for focus formation.  (B) Replicate plates of DMSO (not shown) or 
U0126 treated Rat-1 cells were assayed for phosphorylated ERK, total ERK, or PARP 
(loading control) by western blot analysis. 
 
To evaluate the role of MEK1/2 and ERK1/2 signaling in LMP1-mediated 
transformation, parallel sets of Rat-1 stable cells were treated for 7 days with DMSO or 
10µM U0126, a MEK1/2 chemical inhibitor.  Cells were then observed for focus formation 
or assessed for ERK1/2 activation by western blot analysis.  U0126 treatment inhibited 
LMP1-mediated block of contact-inhibited growth as measured by focus formation (Fig. 9A).  
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U0126 also blocked LMP1-induced ERK1/2 activation (Fig. 9B).  LMP1 expression levels in 
the presence and absence of U0126 were confirmed by western blot analysis to ensure that 
the block in contact-inhibited growth was not due to lack of LMP1 expression (data not 
shown).  These data suggest that ERK1/2 activation is necessary for LMP1-mediated 
transformation of Rat-1 fibroblasts. 
 
DISCUSSION 
 The data presented in this study evaluated the role of the TRAF-binding site in 
LMP1-mediated transformation and LMP1-mediated signal transduction.  Several studies 
have characterized the ability of LMP1 to recruit TRAFs 1, 2, 3 and 5 to CTAR1 through a 
consensus TRAF-binding site at positions 204 to 208 (4, 24, 35, 37, 38, 50, 51).  Substitution 
of the proline and glutamine residues to alanines, positions 204 and 206 respectively, in the 
TRAF-binding site has been demonstrated to disrupt all TRAF1 and TRAF2 binding and 
most, but not all, TRAF3 binding (35).  In agreement with these data, substitution of the 
proline and glutamine residues to alanines in the TRAF-binding site (LMP1-204/6AA), 
which impairs all but some TRAF3 binding (35), greatly impaired LMP1-mediated block of 
contact-inhibited growth.  Accordingly, mutation of the threonine at position 208 to an 
alanine, which has been demonstrated to not affect TRAF binding (35), transformed rodent 
fibroblast to similar levels as wild-type LMP1. 
TRAF binding to LMP1 is also aided by the residues surrounding the TRAF-binding 
site.  While the aspartic acid residue at position 209 is not necessary for TRAF binding, the 
aspartic acid residue at position 210 is required for TRAF binding (4, 50). The aspartic acid 
at position 210 is also part of a destruction box motif that binds the E3-ubiquitin ligase 
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component homologue of Slimb (HOS), which plays a role in regulating LMP1-mediated 
IκBα-dependent NFkB signaling (34, 46).  These data are corroborated by the finding in this 
study that 1-208 is non-transforming even though an intact TRAF-binding site is present.  
Interestingly, although 1-208 is non-transforming it is still able to modulate effects on 
GSK3β, Rb, p27 and plakoglobin indicating that some signal transduction properties remain 
intact.  Furthermore, these data indicated that activation of these pathways is not sufficient 
for Rat-1 fibroblast transformation.  Also, the aspartic acid at position 211 and the serine at 
position 215 were recently demonstrated to be phosphorylation sites within LMP1 (5).  While 
these residues were not demonstrated to affect TRAF binding, their close proximity to the 
TRAF-binding site could regulate TRAF-LMP1 through their phosphorylation status. 
Specifically CTAR1 has been demonstrated to recruit TRAF1-TRAF2 or TRAF3-
TRAF5 heterodimers, with the binding of the heterodimers being mutually exclusive (12).  
Signal transduction mediated by the LMP1-TRAF interaction is more complex than simply 
recruiting the TRAFs to LMP1.  In knockout TRAF2 and TRAF5 MEFs, TRAF6 is essential 
for NFkB signaling, but in mouse lymphoma cells TRAF3 is central for such activation (31, 
51, 52).  TRAF-LMP1 interactions are further complicated by the role of adapter molecules 
in mediating binding, especially in CTAR2-TRAF binding.   The finding that co-expression 
of either dnTRAF2 or dnTRAF3 inhibited, but did not fully block, but inhibited, LMP1-
mediated transformation indicates that TRAF2 and TRAF3 contribute to transformation but 
that they are not the sole players in mediating this effect.   
 CTAR1 has been demonstrated to be necessary for B-lymphocyte transformation by 
EBV as well as for LMP1-mediated transformation of rodent fibroblasts (24, 33).  CTAR1 
has the unique ability to induce expression of EGFR, TRAF1, and can deregulate molecules 
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involved in G1/S cell-cycle progression such as Id1, the cdki p27, CDK2 and Rb (12, 17, 26, 
29, 35-37).  Furthermore, although CTAR1 does not induce the bulk of LMP1-mediated 
NFκB activation, CTAR1 induces specific forms of NFκB through both canonical and 
noncanonical pathways while also being responsible for the activation of the PI3K-Akt 
signaling pathway (1, 10, 32, 33, 37, 44, 48). 
In this study the activation of the PI3K-Akt-GSK3β signaling pathway as well as the 
deregulation of several cellular markers involved in G1/S cell-cycle progression, and the cell 
adhesion protein plakoglobin were also mapped to CTAR1.  However, deletion or mutation 
of CTAR1 in full-length LMP1 revealed that another signaling motif in LMP1 can augment, 
but not transform, the LMP1-mediated activation of the PI3K-Akt-GSK3β pathway, 
deregulate cell-cycle markers such as p27, Rb, and CDK2, and decrease levels of 
plakoglobin.  The motif associated with redundancy in LMP1-mediated signaling does not 
appear to be CTAR2, as mutation of both CTAR1 and CTAR2 (A5-Y384G or A5-378Stop) 
resulted in decreased levels of p27.  In contrast, CTAR1 is essential in LMP1 signal 
transduction in the context of a truncated molecule, 1-208-A5 or 1-220-A5.   
The absolute requirement for CTAR1 in a truncated form of LMP1 but not in full-
length LMP1 suggests that the motif that provides signaling redundancy is located between 
amino acids 220 and 378.  This motif is not sufficient for transformation as ablation of 
CTAR1 in any context yields a non-transforming phenotype.  Putative Janus kinase 3 (JAK3) 
binding sites have been identified in the region between CTAR1 and CTAR2; however the 
ability of LMP1 to bind and activate JAK3 has been controversial as two different studies 
report conflicting conclusions (20, 21). Another motif of interest is a putative TRAF binding 
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site at amino acids 320-324, although deletion of amino acids 232-351 did not affect TRAF 
binding (22).  It is also possible that the motif in question has yet to be identified. 
In this study ERK1/2 activation was mapped to CTAR1 and this activation was 
demonstrated to be necessary for LMP-1 mediated transformation of rodent fibroblasts.  
ERK1/2 responds to various mitogens and growth factors and initiate changes in cellular 
proliferation and differentiation.  These data support previous findings suggesting that 
LMP1-mediated ERK1/2 activation requires TRAF2 or TRAF5 (6).  Furthermore, LMP1-
mediated transformation and ERK1/2 activation are mediated by MEK1/2 as inhibition of 
MEK1/2 by the chemical inhibitor U0126 blocked both transformation and ERK1/2 
activation.  Although the role of ERK1/2 activation in LMP1-mediated transformation 
remains to be fully determined, a study demonstrated that the ability of LMP1 to affect 
RECK, a metastasis suppressor gene, is dependent on ERK activation (30). 
We have previously revealed that CTAR1-induced activation of PI3K-Akt signaling, 
but not IκBα-dependent NFκB-signaling, is necessary for Rat-1 fibroblast transformation 
(33).  The data presented in this study revealed that activation of PI3K-Akt signaling and 
deregulation of cell-cycle markers associated in G1/S transition is necessary but not 
sufficient for rodent fibroblast transformation.  However, activation of ERK1/2 signaling is 
demonstrated to be necessary for Rat-1 fibroblast transformation.  The activation of ERK1/2 
signaling by only those LMP1 constructs that have a transforming phenotype underscores the 
importance of ERK1/2 activation in LMP1-mediated transformation.  It is becoming clear 
that LMP1 induces a variety of stimuli to affect cellular expression and induce 
transformation, and that at least several of these signal transduction pathways are needed to 
work in unison for transformation to take place. 
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CHAPTER FIVE 
 
 
 
 
 
 
Conclusions
 From the onset of primary infection and the establishment of latency, EBV and the 
host immune system participate in an interplay of viral replication and host immune 
surveillance.  In most individuals, EBV infection and persistence are asymptomatic, and the 
carrier is unaffected by EBV.  In some instances environmental, genetic, or host immune 
system-suppressing factors tilt the regulatory balance between EBV and the host, leading to 
EBV-induced oncogenesis.  The ubiquitous nature of EBV combined with its association 
with a wide range of malignancies, of both lymphoid and epithelial origin, that are endemic 
in several regions of the world make EBV a significant health risk.  Understanding the 
molecular mechanisms of EBV-mediated oncogenesis is necessary to properly design 
effective therapies. 
 EBV-induced disease is mainly associated with three types of latent gene expression, 
characterized by the pattern of viral gene expression.  Latent membrane protein 1 (LMP1) is 
expressed in type II and type III latency and is expressed in several types of EBV-associated 
diseases.  LMP1 acts as a prototypical oncogene as it is able to transform rodent fibroblasts, 
and EBV lacking LMP1 is unable to transform B-lymphocytes (13, 21).  The transforming 
properties of LMP1 are achieved through the activation of signal transduction pathways 
through its two signaling domains CTAR1 and CTAR2. 
 In chapter two, the requirement for CTAR1 and CTAR2 in LMP1-mediated 
transformation of rodent fibroblasts and the role of the CTARs in the activation of PI3K-Akt 
and NFκB signaling were analyzed.  CTAR1, but not CTAR2, was found to be necessary for 
Rat-1 fibroblast transformation.  Concordant with transformation, CTAR1 but not CTAR2 
was found to be necessary for PI3K-Akt activation and this activation was required for rodent 
fibroblast transformation.  IκBα-dependent NFκB signaling was not necessary for 
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transformation, further hinting at the importance of CTAR1 in LMP1-mediated 
transformation of rodent cells. 
 The CTAR1-induced activation of PI3K-Akt can lead to numerous pathways 
downstream of PI3K or Akt being activated.  Of particular interest was the inactivation, 
through phosphorylation, of the Akt target GSK3β, as it has been demonstrated to play a role 
in the stabilization of the proto-oncogene β-catenin.  β-catenin can interact with T-cell 
factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors and induce 
transcription (19).  However, although β-catenin is detected at increased levels in the nuclei 
of epithelial cells expressing LMP2A, EBV-positive lymphoid cells did not have enhanced 
protein levels of β-catenin in their nuclei, although increased cytoplasmic levels were 
detected (9, 16).  In Rat-1 cells expressing LMP1, cytoplasmic and nuclear β-catenin levels 
were unchanged, suggesting that the inactivation of GSK3β by LMP1 does not target β-
catenin.  Cytoplasmic β-catenin can interact with E-cadherin and contribute to cell adhesion.  
Interestingly, LMP1 decreases E-cadherin levels suggesting that LMP1 may target a pool of 
β-catenin that is independent of GSK3β regulation. 
 Alternatively the inactivation of GSK3β by LMP1 could lead to other cellular effects 
that are β-catenin-independent.  Stimulation of apoptotic signals has been shown to lead to 
the specific activation of GSK3β pools in the mitochondria.  Furthermore, activation of PI3K 
can lead to the translocation of Akt into the mitochondria where it can target and inactivate 
GSK3β, thus inhibiting the induction of the apoptotic program (2).  Also, the cellular 
localization of LMP1 is not restricted to the plasma membrane and a portion of LMP1 can 
localize to other cellular membranes.  These observations suggest a model where LMP1 
could target GSK3β to prevent programmed cell death by activating PI3K at the plasma 
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membrane, leading to the subsequent activation and translocation of Akt to the mitochondria, 
followed by GSK3β inhibition and block of the apoptotic program.  Alternatively, a subset 
population of LMP1 could activate this anti-apoptotic program by signaling from the 
mitochondrial membrane. 
 Another possible target of LMP1-induced Akt activation is the ubiquitin ligase 
murine double minute 2 (MDM2), which in turn can regulate the protein levels of the pro-
apoptotic p53.  Phosphorylation of MDM2 by Akt increases the targeting of p53 for 
proteasomal degradation.  Increased levels of MDM2 protein levels have been detected in 
EBV positive NPC, however the presence of phosphorylated MDM2 was not analyzed (22).  
LMP1 also targets p53 activity through the induction of the A20 gene (11), suggesting that 
regulation of p53 activity by LMP1 is important for the promotion of cell survival. 
 The LMP1-driven activation of Akt could also lead to the subsequent activation of 
other Akt targets that provide a pro-growth environment.  Forkhead box O-class 3a 
(FOXO3a) is a member of the forkhead transcription factor family and its activity can be 
regulated by Akt-mediated phosphorylation.  FOXOs act as tumor suppressors regulating cell 
proliferation, inhibiting apoptosis, and protecting cells from DNA damage and oxidative 
stress (12).  Interestingly the p27Kip1 promoter has a consensus FOXO-binding site 
suggesting that p27Kip1 gene expression could be regulated by a FOXO family member.  
LMP1 can regulate p27Kip1 at the transcriptional level and it had been hypothesized that this 
regulation was perhaps taking place though the Id family of proteins (10).  However, it is 
possible that LMP1-mediated activation of FOXO3a, through the activation of Akt, could in 
turn lead to suppression of p27Kip1 gene expression (5).  The ability of LMP1 to target p27Kip1 
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gene expression through multiple mechanisms (e.g. Id1 or FOXO3a) may provide LMP1 
with a mechanism of action under different cell types or cellular environments. 
 The finding, from chapter two, that IκBα-dependent NFκB signaling is not necessary 
for LMP1-mediated transformation corroborated the requirement for CTAR1 but not CTAR2 
for rodent fibroblast transformation.  The partial inhibition of transformation, as observed by 
smaller foci and smaller colonies in soft agar, by the NFκB inhibitor also suggests that the 
NFκB activity from CTAR1 provides growth properties that can accentuate LMP1’s 
transforming potency.  Interestingly, IκBα-dependent NFκB signaling was demonstrated to 
be necessary for LMP1-driven B-lymphocyte transformation (14).  This suggests that the role 
of NFκB signaling, and perhaps other signaling pathways, may vary from one cell type to 
another.   
As only IκBα-dependent NFκB signaling was assayed for its role in LMP1-induced 
transformation, the role of other forms of NFκB signaling in LMP1-mediated transformation 
remains to be analyzed.  Although CTAR2 induces the bulk of NFκB activity, through 
p50/p65 dimers, CTAR1 induces a more complex signal, with three different types of NFκB 
dimers (p52/p65, p52/p50, and p50/p50) being induced.  LMP1 can also activate NFkB 
signaling through IκBα-independent mechanisms and these other pathways may prove to be 
necessary for LMP1-induced transformation of epithelial cells.  The role of the different 
NFκB forms as well as their interplay with other transactivating factors that contribute to the 
regulation of LMP1-induced genes remain to be fully elucidated. 
 The absolute dispensability of CTAR2 in LMP1-mediated transformation of epithelial 
and lymphocytic cells, even in the context of EBV-mediated transformation, leaves the role 
of CTAR2 in EBV oncogenesis unanswered.  Amongst the best characterized functions of 
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CTAR2 has been its ability to induce the majority of LMP1-induced NFκB signaling as well 
as its ability to induce JNK-signaling.  While the activation of these two signaling pathways 
is not necessary for transformation in vitro, these pathways could contribute to the 
modulation of other aspects associated with the viral life cycle.  Indeed, NFκB can regulate a 
wide array of molecules involved in the host immune response, from cytokines to 
interleukins to adhesion molecules.  Furthermore, although CTAR2 is also dispensable in 
EBV-mediated transformation in vitro, as outgrowth of LCLs does not require CTAR2, 
lymphocytes infected with EBV lacking CTAR2 have a small growth defect indicating that 
CTAR2 provides some growth-inducing properties.  It is also plausible that CTAR2 could 
contribute to the regulation of other viral genes during latency through the induction of 
NFκB, JNK or other signaling pathways.  Alternatively, CTAR2 could act by merely 
competing against cellular molecules that would otherwise impair cellular proliferation or 
growth.  As such, TRADD binding by CTAR2 may impair apoptotic signaling that is 
TRADD-dependent. 
 In chapter three, the signal transduction properties and transformation properties of 
six LMP1 sequence variants were analyzed.  The sequence variations in all variants are 
spread out throughout the molecule but CTAR1 and CTAR2 sequences are perfectly 
conserved.  Concurrent with CTAR1 being necessary for transformation and activation of 
PI3K-Akt signaling, all sequence variants transformed rodent fibroblasts in a PI3K-Akt-
dependent manner and deregulated a variety of cell-cycle progression markers that have been 
mapped to CTAR1.  The variants also induced homotypic adhesion. 
The major difference within the sequence variants was their ability or lack thereof to 
bind HOS, an E3 ubiquitin ligase component that regulates the turnover of IκBα and β-
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catenin (20).  The difference in HOS binding only resulted in a small, but statistically 
significant, difference in their ability to induce NFκB signaling, while not correlating directly 
with the levels of IκBα or β-catenin.  These data correlate with previous data suggesting that 
IκBα-dependent signaling is not a major factor in LMP1-mediated transformation of rodent 
fibroblasts.  Although HOS binding did not correlate with IκBα or β-catenin protein level, 
the small effect on NFκB signaling suggests that HOS targets some part of the NFκB 
signaling cascade.  The small effect on NFkB signaling mediated by HOS could be related to 
a small decrease in IκBα levels that were not detected by western blot analysis.  
Interestingly, although HOS is an E3-ubiquitin ligase component and it binds LMP1, it does 
not regulate the turnover of LMP1 (20).  The regulation of NFκB signaling through HOS 
adds another layer of complexity to the regulation of LMP1-mediated NFκB signaling. 
The lack of significant differences in the transformation or signal transduction 
potential of the LMP1 variants suggests that the sequence variations do not provide a 
transforming or signaling advantage to the LMP1 sequence variants.  A recent study 
demonstrated that several of the amino acid changes in the sequence variants are found 
within predicted HLA-restricted epitopes.  Moreover, the study found that the LMP1 
sequence variant that is most prevalent in tumors from regions where NPC is endemic, China 
1, had amino acid differences in epitopes that are HLA-A2 or –A24 restricted.  Concordant 
with these data, most NPC patients from this region are HLA-A2 or –A24 restricted (6).  
These specific changes may result in decreased binding and presentation of the epitopes by 
MHC class I and/or lower recognition by the T-cell receptor, thus providing a way to 
suppress host immune recognition.  The lack of significant differences in the transforming 
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and signaling potential of the LMP1 sequence variants compounded by the HLA-epitope data 
suggest that the amino acid differences provide an immune modulatory advantage to LMP1. 
 In chapter four, the role of the TRAF-binding domain of LMP1 was analyzed in the 
context of rodent fibroblast transformation.  CTAR1 contains a consensus TRAF binding 
domain at positions 204 to 208 (PQQAT) that directly associates with TRAF1/2 or TRAF 3/5 
heterodimers, with the heterodimers binding being mutually exclusive (4).  The role of 
specific TRAFs in LMP1-induced signal transduction is complicated by the finding that the 
presence or absence of specific TRAFs can alter the importance of a specific TRAF in signal 
transduction.  For example, the absence of TRAF1 in mouse embryo fibroblasts (MEF) has 
been linked to an increased dependency on CTAR2 for LMP1 to mediated signal 
transduction (4, 7, 8).  Also, LMP1 expressed in TRAF2 and TRAF5 knockout MEFs is able 
to activate NFκB signaling at comparable levels seen in wild-type MEFs, and this activation 
is dependent on TRAF3 and TRAF6 (14, 17).  In contrast, in mouse lymphoma cells NFκB 
activation and IgM secretion are almost completely TRAF3 dependent (23, 24).   
These data indicate that LMP1-TRAF association and the resulting signal 
transduction can differ from one cell type to another.  These differences could also be a result 
of varying levels of endogenous TRAF levels in different cells.  The ability of LMP1 to 
direct its signal transduction potential to specific pathways could also be related to the 
stoichiometry of TRAFs associated with the CTARs.  Furthermore, the affinity of LMP1 for 
TRAFs can be altered by truncations of the molecule.  Deletion of CTAR2, for example, 
augments the ability for LMP1 to recruit TRAF1 as compared to full-length LMP1 (23).  The 
possibility that truncations, substitutions, or deletions of regions in LMP1 may affect TRAF 
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affinity to other areas of the molecule, further complicates the analysis of LMP1-mediated 
signal transduction from LMP1 mutants. 
 Beyond signaling, TRAF3 binding to CTAR1 mediates the ubiquitination and 
subsequent proteasomal degradation of LMP1 through its amino-terminal RING finger 
domain.  Expression of dnTRAF3, which lacks the RING finger domain, inhibited NFκB 
signaling and also impaired the ubiquitination of LMP1 (18).  These data are corroborated by 
the increased expression levels of LMP1 mutants that have amino acid substitutions within 
the PxQxT TRAF binding domain in chapter four.  Another study reported that the short 
amino-terminal end of LMP1 is also necessary for the proteasomal degradation of LMP1 (1).  
However, there appears to be another level of regulation of LMP1 turnover, as deletion of the 
last 166 (221-386) or 177 (232-386) amino acids also results in increased protein levels, and 
as mutation of CTAR1 in these mutants further increases their protein levels.  The increased 
levels of expression in the truncated forms of LMP1 could be due to turnover mediated from 
the recruitment of TRAFs to CTAR2.  Indeed as shown in chapter four, mutation or deletion 
of CTAR2 resulted in increased protein levels of the LMP1 mutants.  While these data do not 
directly demonstrate that CTAR2 plays a role in the regulation of LMP1 ubiquitination and 
turnover it suggests that TRAF binding and/or recruitment may mediate this effect. 
Another level of post-translational regulation of LMP1 is its phosphorylation.  Four 
sites within LMP1 have been identified as phosphorylation sites; serines at positions 211, 215 
and 313, and threonine 324 (3, 15).  A T324Q substitution inhibited the transforming ability 
of LMP1 whereas substitution of the serine at position 313 did not impair the transforming 
potential of LMP1 (15).  The role of the other two serine residues has yet to be determined, 
although phosphorylation of S211 is dependent on the phosphorylation of S215 (3).  
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Phosphorylation of these residues could be involved in regulating the interaction of LMP1 
with its cellular binding partners, thus regulating the ability of the transducing potential of 
LMP1. 
Establishing the roles of the different signal transduction pathways activated by 
LMP1 is important to understanding the molecular mechanisms through which LMP1 
induces oncogenesis.  The requirement for PI3K-Akt and MEK-ERK activation in LMP1-
mediated transformation of rodent fibroblasts indicates that LMP1 induces transformation by 
through the activation of several pathways.  While PI3K-Akt activation is necessary for 
transformation, it is not sufficient to restore transformation in LMP1 mutants lacking CTAR1 
(unpublished observations).  The finding in chapter four demonstrating that mutation of the 
TRAF-binding domain or LMP1 containing the first 208 amino acids, both of which are non 
transforming, could still activate PI3K-Akt further indicates that this pathway is not 
sufficient to induce transformation of rodent cells.  Distinguishing whether PI3K-Akt 
activation is a direct product of LMP1 signaling or a by-product of LMP1 induced cellular 
growth would yield an insight on molecular mechanisms of LMP1-induced oncogenesis. 
Consequently, it is unknown whether MEK-ERK activation is sufficient to rescue 
transformation from cells expressing LMP1 deleted for CTAR1.  Unlike PI3K-Akt 
activation, ERK1/2 activation was detected only in LMP1 mutants that had a transforming 
phenotype, indicating that activation of this pathway is closely linked to LMP1-mediated 
transformation of rodent fibroblasts.  Considering that cellular transformation is a 
complicated process, the multiple cellular processes that are affected by LMP1, and the 
presence of cross-talk between signal transduction pathways, it would be unexpected if one 
signal transduction pathway is responsible for LMP1-mediated transformation. 
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The data presented here provide a complex model of the signal transduction events 
associated with LMP1-mediated cellular transformation (Fig. 1).  The ability of LMP1 to 
adapt to the host immune system through the incorporation of sequence variations that do not 
affect its transforming and signal transduction potential also underscores the role of LMP1 in 
EBV-induced disease.  Through CTAR1, LMP1 drives cellular transformation through the 
hijacking of various components of the cellular machinery.  Dissecting the role of these 
cellular components in LMP1-mediated transformation should yield a deeper understanding 
of EBV-induced pathogenesis. 
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FIG. 1.  Signal transduction pathways modulated by LMP1.  CTAR1, and a site between 
CTAR1 and CTAR2, activates the PI3K-Akt signaling pathway, with the subsequent 
phosphorylation of the Akt targets MDM2, GSK3β, and Foxo3A.  These two sites also 
modulate factors associated with G1/S cell cycle progression.  In contrast, CTAR1 uniquely 
activates the MEK1/2-ERK1/2 signaling pathway.  Activation of MEK1/2-ERK1/2 and 
PI3K-Akt (highlighted in green) are necessary for LMP1-mediated Rat-1 fibroblast 
transformation. 
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